The Chemistry of Fentanyl and Its Implications on Brain Development: A Review

The Chemistry of Fentanyl and Its Implications on Brain Development: A Review | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review The Chemistry of Fentanyl and Its Implications on Brain Development: A Review Alli, A. O. This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-9288777/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Since its discovery in 1960 by Paul Janssen, fentanyl has emerged as one of the central substances in the global opioid crisis because of its high potency (50–100 times that of morphine) and rapid penetration through the blood-brain barrier. Following the PRISMA 2020 guidelines for reporting systematic reviews and meta-analyses, this systematic review synthesizes the results of ten empirical studies (2018–2025) analyzing fentanyl's chemical characteristics and neurodevelopmental effects. The findings demonstrate that fentanyl disrupts synaptic development through µ-opioid receptor (MOR) agonism, induces neuronal apoptosis via oxidative stress pathways, alters gene expression in reward circuits, and produces lasting cognitive deficits. After perinatal exposure, preclinical studies have revealed persistent dysfunction of the somatosensory system and transcriptomic alterations in the nucleus accumbens. Clinical meta-analyses have demonstrated that children exposed to such chemicals suffer from serious cognitive and motor impairments. This review addresses the critical gap in integrating the specific molecular chemistry of fentanyl, its phenylpiperidine structure (C₂₂H₂₈N₂O), lipophilicity (logP ~ 4.0), and high receptor affinity with neurodevelopmental mechanisms. Future research should focus on computational chemistry approaches to design safer analogs and neuroprotective strategies. This study contributes to Sustainable Development Goal 3 (Target 3.5) by providing an evidence base for chemistry-informed harm reduction and prevention strategies. Biological Chemistry Special Education Chemical Biology Fentanyl Neurodevelopment µ-Opioid Receptors Brain Toxicity Chemistry Prenatal Exposure Adolescent Brain Figures Figure 1 Figure 2 1. Introduction Over the past 20 years, opioid misuse has become a major public health issue worldwide. Both medical and non-medical uses have contributed to rising addiction and overdoses (Jalali, 2020; World Health Organization (WHO), 2025 ). Initially, prescription opioids, such as oxycodone, drove the epidemic, but illicit opioids subsequently became dominant, particularly in North America and Europe (Centers for Disease Control and Prevention (CDC), 2025 ). Volkow and Blanco ( 2021 ) indicated that synthetic opioids, especially fentanyl and its analogs, now drive this stage of the epidemic (Mattson et al., 2021 ). These substances are widely available in illegal markets, often mixed with other drugs without the user’s knowledge, creating unpredictable overdose risks (O'Donnell et al., 2021 ). Friedman et al. ( 2025 ) characterized this as a "fourth wave" involving polysubstance use (Ciccarone, 2021 ). Despite extensive research on mortality, the biological consequences of fentanyl exposure remain less explored, particularly regarding brain development (Alzu'bi et al., 2024 ; Hauser & Knapp, 2018 ; Dwivedi & Haddad, 2024 ; Posa & Porfilio, 2025 ; Williamson & Kermanizadeh, 2024 ). Exposure among vulnerable groups, including adolescents and those with early life exposure, appears to be increasing (Alipio et al., 2021 ; Manuel et al., 2023 ; Olusakin et al., 2023 ; Pickens et al., 2025 ). This review addresses this gap by examining the association between fentanyl exposure and brain development, integrating chemistry, pharmacology, and neuroscience. This approach contributes to Sustainable Development Goal 3, Target 3.5, by informing harm-reduction strategies and supports Sustainable Development Goal 4 by increasing health risk awareness. 1.1 Fentanyl as a Synthetic Opioid Fentanyl is a fully synthetic phenylpiperidine opioid widely used for anesthesia and severe pain management purposes. Its effects are rapid and potent when administered under medical supervision (Armenian et al., 2018 ). Its high potency is derived from strong µ-opioid receptor binding, which also produces respiratory depression risk, even at moderate doses. Its lipophilic properties enable rapid blood-brain barrier crossing, explaining its rapid central nervous system effects (Han et al., 2022 ). These features create medical utility but also pose a high risk. Illicitly manufactured fentanyl is increasingly appearing in drug markets, sometimes mixed unknowingly with other substances, creating uncertainty about its composition and strength (Volkow & Blanco, 2021 ; Mattson et al., 2021 ). This unpredictability increases the risk of overdose and may explain the rising mortality (O'Donnell et al., 2021 ). Although the pharmacological effects have been documented, the implications for brain development remain unclear. This review bridges this gap by connecting the chemical and pharmacokinetic properties of these chemicals with neurodevelopmental processes. 1.2 Importance of Studying Brain Development Effects Understanding the effects of fentanyl on brain development is critical because the developing nervous system is highly sensitive to chemical influences. During the critical period of prenatal stages and adolescence, the brain undergoes neurogenesis, synaptogenesis, synaptic pruning, and myelination, which are necessary for functional neural circuits (Hauser & Knapp, 2018 ; Dwivedi & Haddad, 2024 ). Disruption by potent opioids can produce lasting effects in adulthood. Fentanyl's lipophilicity and strong µ-opioid receptor affinity allow rapid central nervous system entry, interfering with neurotransmission and signaling pathways that guide neural maturation (Han et al., 2022 ; Armenian et al., 2018 ). Animal studies suggest that early life exposure disrupts synaptic development, changes gene expression, and alters neural circuit formation (Alipio et al., 2021 ; Olusakin et al., 2023 ). Human studies have linked prenatal opioid exposure to cognitive difficulties, behavioral problems, and delayed developmental milestones (Yeoh et al., 2019 ; Balalian et al., 2023 ). These risks are particularly concerning given the prevalence of fentanyl in illicit markets, where exposure may occur unknowingly with widely varying doses (Mattson et al., 2021 ; O'Donnell et al., 2021 ). Understanding how the chemical properties of fentanyl translate into developmental outcomes is essential for guiding clinical practice, informing public health interventions, and supporting harm reduction policies aligned with Sustainable Development Goal 3, Target 3.5. 1.3 Research Objectives and Scope This review examines the chemistry of fentanyl and its implications for brain development through (i) analysis of the molecular structure and physicochemical properties influencing pharmacokinetics and pharmacodynamics; (ii) exploration of central nervous system interactions, particularly through µ-opioid receptors; and (iii) review of neurodevelopmental outcomes from exposure during sensitive periods, including prenatal development and adolescence. The review draws primarily on studies from 2018 to 2025 for recent pharmacological and developmental evidence, with older studies included where relevant. Both preclinical and clinical studies are considered to provide comprehensive developmental-stage coverage. 2. Methodology This systematic review followed the PRISMA 2020 guidelines (Page et al., 2021 ) to ensure methodological clarity and reproducibility. Searches were conducted in PubMed, Scopus, Web of Science, and Embase using combinations of terms: "fentanyl," "synthetic opioids," "brain development," "neurodevelopment," "µ-opioid receptor," "blood-brain barrier," "prenatal exposure," and "adolescent brain." Boolean operators (AND, OR) were used to identify relevant studies. The search strategy was designed to identify peer-reviewed articles examining the chemical, pharmacological, or neurodevelopmental effects of fentanyl in humans, animals, or in vitro models. This review considered studies published between 2018 and 2025. The inclusion criteria were as follows: (1) examination of fentanyl or fentanyl analogs; (2) focus on brain development, neurodevelopment, or neurotoxicity; (3) empirical data from experimental, clinical, or epidemiological studies; and (4) peer-reviewed publication in English. The exclusion criteria eliminated editorials, commentaries, non-peer-reviewed sources, conference abstracts, duplicates, and studies not directly related to brain development or lacking fentanyl-specific data. After duplicate removal, the titles and abstracts were screened independently by two reviewers. Full texts were reviewed to confirm eligibility, and borderline cases were resolved through discussion and consensus. Data extraction captured the study design, sample characteristics, opioid exposure type, main findings, and quality indicators. The risk of bias was assessed using appropriate tools: SYRCLE for animal studies, the Newcastle-Ottawa Scale for observational studies, and Cochrane tools for clinical trials. The evidence was grouped into four themes: early life exposure, neuronal and synaptic changes, cognitive outcomes, and public health implications. 2.1 PRISMA 2020 Flow Diagram 3. History of Fentanyl: Development and Implications Fentanyl was first synthesized in 1960 by Dr. Paul Janssen, a Belgian physician and medicinal chemist at Janssen Pharmaceutica in Beerse, Belgium (Barletta et al., 2025 ; Stanley, 2014 ). Janssen developed fentanyl as part of a systematic research investigating phenylpiperidine derivatives with enhanced analgesic properties compared to existing opioids. The compound was designed for rapid onset and short duration characteristics, which are desirable for surgical anesthesia. It was clinically approved in 1963 in Western Europe, and entered the U.S. market in 1968 under the brand name Sublimaze (combined with droperidol as Innovar) (Jelínková, 2024 ). Subsequent standalone approvals were made in 1972. The transdermal patch (Duragesic) developed in the mid-1990s expanded applications to chronic pain management, while oral formulations, including Actiq and Onsolis, provided alternative delivery mechanisms (Leppert et al., 2018 ). 3.1 Clinical Advantages and Neurodevelopmental Disadvantages Clinical Advantages Rapid blood-brain barrier penetration enables effective anesthesia with minimal cardiovascular depression. Short durations reduce prolonged central nervous system depression in surgical contexts. Transdermal delivery provides controlled dosing for chronic pain without repeated central nervous system activation (Davis & Behm, 2020 ; Dong et al., 2025 ; Henthorn & Mikulich-Gilbertson, 2018 ; Hussien & Rabie, 2019 ; Ramos-Matos et al., 2023 ). Neurodevelopmental Disadvantages Extreme potency (50–100× morphine) creates a narrow therapeutic index, increasing the risk of hypoxic brain injury during overdose. High lipophilicity (logP ~ 4.0) facilitates rapid entry into the central nervous system, overwhelming the developing neural circuits. Strong µ-opioid receptor affinity disrupts neurotransmitter homeostasis, which is critical for synaptogenesis and myelination. Illicit manufacturing variability creates unpredictable exposure levels, which are particularly dangerous during pregnancy (Davis & Behm, 2020 ). 4. Chemistry of Fentanyl: Physical and Chemical Properties Table 1 Physicochemical Properties of Fentanyl Property Value/Description Significance for Brain Development IUPAC Name N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide Defines molecular scaffold for structure-activity relationships Molecular Formula C₂₂H₂₈N₂O Phenylpiperidine class distinguishes from morphinan opioids Molecular Weight 336.471 g/mol Affects transport kinetics across biological membranes Chemical Class Synthetic phenylpiperidine opioid Enables complete chemical synthesis (unlike plant-derived morphine) LogP (Lipophilicity) ~ 4.0 (highly lipophilic) Rapid blood-brain barrier penetration; accumulates in lipid-rich neural tissue Aqueous Solubility Slightly soluble Limits intravenous formulation options; favors lipid-based delivery pKa 8.99 (tertiary amine) Ionization state affects µ-opioid receptor binding affinity at physiological pH Melting Point 87–88°C Physical stability affects formulation and illicit manufacturing Primary Functional Groups Tertiary amine (piperidine), aromatic phenyl rings, amide linkage Tertiary amine forms ionic bond with Asp3.32 of µ-opioid receptor; aromatic rings enable hydrophobic interactions Volume of Distribution Large (4–6 L/kg) Extensive tissue distribution including brain, lungs, adipose tissue Plasma Protein Binding 80–85% Affects free drug concentration available for central nervous system entry Metabolism Hepatic CYP3A4 → norfentanyl Variable metabolic rates affect duration of central nervous system exposure Elimination Half-life 3–12 hours (context-dependent) Prolonged exposure in neonates due to immature clearance systems Potency Relative to Morphine 50–100 times more potent Small dosing errors produce catastrophic central nervous system depression Table 1_Source: Compiled from National Center for Biotechnology Information ( 2026 ), European Monitoring Centre for Drugs and Drug Addiction (2025) , Han et al. ( 2022 ), and Armenian et al. ( 2018 ). 4.1 Molecular Structure and Functional Groups The chemical structure of fentanyl features a central piperidine ring with an anilide group at the 4-position and a phenethyl side chain. This arrangement provides a flexible three-dimensional shape that facilitates biological target interactions. Aromatic rings and amide linkages enhance receptor-binding strength and chemical stability (Armenian et al., 2018 ). Key functional groups include : Tertiary amine : Interacts ionically with µ-opioid receptors (specifically Asp3.32 residue) Aromatic phenyl rings : Enable hydrophobic interactions in the receptor binding site Amide linkage (-CONH-) : Contributes to molecular stability and receptor affinity together, these features explain fentanyl's strong µ-opioid receptor affinity, related to both analgesic and psychoactive effects, and its exceptional potency compared to morphine. 4.2 Synthetic Pathways and Analogues Fentanyl's synthetic origin allows for controlled pharmaceutical production but also enables unregulated manufacturing (Larnder et al., 2022 ; Financial Action Task Force [FATF], 2022). The phenylpiperidine structure permits modifications at multiple chemical positions, producing numerous analogs with varying pharmacological properties (Armenian et al., 2018 ). Structural changes, although sometimes small at the molecular level, can produce dramatically different effects on potency, receptor binding, and duration. Some analogs exceed the potency of fentanyl, increasing the risk of overdose at very low concentrations. These analogs create unpredictability in illicit supplies, with users often unaware of the composition or concentration, complicating detection and clinical management (Clinton et al., 2021 ). 4.3 Pharmacokinetics (ADME) Absorption High lipophilicity enables rapid absorption through intravenous, transdermal, and transmucosal routes, with quick blood-brain barrier crossing (Han et al., 2022 ; Taghizadehghalehjoughi et al., 2024 ). Distribution Fentanyl distributes widely into highly perfused tissues and lipid-rich areas including brain, lungs, and adipose tissue, reflecting large volume of distribution (4–6 L/kg). This supports strong central effects but creates unpredictability, with potential accumulation during repeated exposure (Armenian et al., 2018 ). Metabolism Hepatic CYP3A4 metabolism produces norfentanyl. Individual genetic and physiological differences influence metabolic rates, affecting duration and intensity of effects (Wilde et al., 2019 ). Elimination Primarily renal, though clearance varies with metabolic capacity and usage patterns. These features rapid absorption, wide distribution, and variable metabolism explain fentanyl's potency while narrowing the margin between therapeutic and toxic doses (Barletta et al., 2025 ). 4.4 Pharmacodynamics Fentanyl primarily exerts its effects through µ-opioid receptor activation. µ-Opioid receptors are distributed throughout the central nervous system, particularly in areas associated with pain, reward, and autonomic control. Binding triggers intracellular changes, such as reduced adenylate cyclase activity, decreased cyclic AMP levels, and altered ion channel function (reduced calcium influx and increased potassium efflux), resulting in reduced neuronal activity and neurotransmitter release (Armenian et al., 2018 ; Han et al., 2022 ; Taghizadehghalehjoughi et al., 2024 ). This explains the analgesic and sedative effects but also disrupts normal synaptic processes, particularly consequential during brain development, where timing and signaling are critical (Hauser & Knapp, 2018 ). These effects extend beyond pain relief to euphoria, sedation, and respiratory depression. Brainstem µ-opioid receptor activation reduces respiratory drive, explaining the high overdose risk (Han et al., 2022 ; Taghizadehghalehjoughi et al., 2024 ). Simultaneously, fentanyl affects reward systems through mesolimbic pathway influence, increasing dopamine via GABAergic interneuron inhibition in the nucleus accumbens, which is associated with reinforcement and dependence (Volkow & Blanco, 2021 ; Mattson et al., 2021 ). Its potency (50–100× morphine) is related to strong receptor binding and rapid central nervous system entry (Armenian et al., 2018 ), creating small margins between therapeutic and harmful doses. Repeated exposure produces tolerance through receptor downregulation and changes in intracellular signaling pathways (Hauser & Knapp, 2018 ). 5. Implications of Fentanyl on Brain Development Fentanyl exposure disrupts brain development during sensitive periods when neural systems are particularly vulnerable (Castro et al., 2023 ; Karatayev et al., 2024 ; Steinfeld & Torregrossa, 2023 ). Prenatal development represents the earliest and most vulnerable stage, involving neurogenesis, neuronal migration, and early circuit formation. Perinatal fentanyl exposure affects somatosensory circuit development and produces long-term behavioral changes (Alipio et al., 2021 ). Transcriptomic studies report gene expression changes in reward and sensory processing pathways (Olusakin et al., 2023 ), indicating early neural organization disruptions in somatosensory cortex and nucleus accumbens. The early postnatal period (infancy through early childhood) involves rapid synaptic pruning, myelination, and network refinement. Children prenatally exposed show developmental delays, behavioral and emotional difficulties (Baig et al., 2024 ; Bierce et al., 2023 ), with ongoing executive functioning issues including cognitive control, emotional regulation, and behavioral organization problems (Spowart et al., 2023 ). Childhood and adolescence involve continued cortical maturation and reward pathway changes. Longitudinal studies report increased emotional and behavioral difficulties over time (Jaekel et al., 2021 ; Balalian et al., 2023 ), with cognitive performance, language development, and behavioral regulation differences persisting into adolescence (Yeoh et al., 2019 ; Rajaprakash et al., 2025 ). 5.1 Mechanisms of Neurotoxicity Fentanyl exposure produces neurotoxic effects via molecular, cellular, and neurochemical processes. Opioid exposure is associated with oxidative stress, neuronal apoptosis, and neuroinflammation, affecting neuronal survival and development, particularly in the cortex and hippocampus (Taghizadehghalehjoughi et al., 2024 ; Han et al., 2022 ). At the synaptic level, fentanyl-induced µ-opioid receptor activation alters intracellular signaling pathways involved in synaptic plasticity and connectivity. Prenatal exposure leads to synaptic dysfunction and neural maturation changes in cortical and limbic circuits that are important for cognition, emotion, and reward processing (Simmons et al., 2023 ). Animal studies have demonstrated altered somatosensory processing, suggesting broader neural network organization issues (Alipio et al., 2021 ). Transcriptomic studies have indicated that fentanyl exposure alters gene expression patterns linked to reward pathways, sensory processing, and neuronal development, particularly in the nucleus accumbens and sensory cortex (Olusakin et al., 2023 ), suggesting long-term developmental pathway changes. Dopaminergic changes in the mesolimbic system are related to altered reward sensitivity and increased addiction risk (Volkow & Blanco, 2021 ). Clinical findings reflect these mechanisms: prenatal opioid exposure is linked to emotional dysregulation, behavioral difficulties, and neurodevelopmental conditions associated with limbic and executive system disruptions (Balalian et al., 2023 ; Baig et al., 2024 ). 5.2 Cognitive and Behavioral Outcomes Prenatal opioid exposure reduces cognitive performance, delays language development, and produces broader developmental deficits (Yeoh et al., 2019 ). Children exposed to cannabis before birth struggle with executive functions, including cognitive control, emotional regulation, and behavioral organization (Spowart et al., 2023 ), displaying externalizing behaviors such as hyperactivity and poor impulse control during early childhood (Baig et al., 2024 ). Prospective infant studies have found developmental delays and early cognitive and behavioral differences within the first year (Bierce et al., 2023 ). Longitudinal research indicates that these impairments persist and may intensify (Volkow & Blanco, 2021 ). Growth pattern analyses have shown elevated emotional and behavioral challenges throughout early and middle childhood, particularly in attention, hyperactivity, and emotional regulation (Jaekel et al., 2021 ). Population studies have reported higher emotional dysregulation and behavioral disorder rates, likely reflecting changes in the limbic system (Balalian et al., 2023 ). Greater opioid exposure during pregnancy, especially prolonged or high-dose exposure, increases the risk of later neurodevelopmental disorders (Wen et al., 2021 ). Preclinical evidence supports these outcomes: prenatal opioid exposure disrupts synaptic function, interferes with neural maturation, and alters reward processing, which is linked to behavioral difficulties and increased addiction vulnerability (Dwivedi and Haddad, 2024 ; Simmons et al., 2023 ). Cortical and limbic networks, particularly those governing executive function and reward, appear to be the most affected (Jiang et al., 2022 ). 6. Empirical Evidence: Fentanyl Effects on Brain Development This section presents detailed analysis of 10 primary empirical studies examining fentanyl's neurodevelopmental effects. Alipio et al., ( 2021 ) reported long-term impairments in somatosensory circuit function and behavior following perinatal fentanyl exposure. Using a novel preclinical model, pregnant dams received fentanyl (10 µg/ml) in drinking water from embryonic day 0 through postnatal day 21. Offspring underwent behavioral assessment, in vitro electrophysiology of primary somatosensory cortex (S1) and anterior cingulate cortex, electrocorticography, and morphological analysis of S1 pyramidal neurons. Molecular analysis included cortical mRNA expression of synaptic transmission and neuronal development markers. Exposed mice showed dose-dependent developmental consequences including newborn withdrawal signs and sensory deficits persisting to adolescence. Electrophysiological recordings demonstrated lasting S1 synaptic excitation reduction: decreased release probability, reduced NMDA receptor-mediated postsynaptic currents, decreased miniature excitatory postsynaptic currents frequency, and increased miniature inhibitory postsynaptic currents frequency. Anterior cingulate cortical neurons showed increased synaptic excitation. Electrocorticography recordings revealed suppressed ketamine-evoked γ oscillations. Morphologically, S1 pyramidal neurons showed reduced dendritic complexity, decreased dendritic length, and smaller soma size. Abnormal cortical mRNA expression of receptors involved in synaptic transmission and neuronal growth was observed. This study provided first evidence that perinatal fentanyl exposure produces lasting behavioral, circuit-level, and synaptic effects through adolescence, with region-specific excitation-inhibition balance alterations disrupting somatosensory processing. Yeoh et al., ( 2019 ) conducted a comprehensive systematic review and meta-analysis following PRISMA and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. They searched PubMed and Embase through August 2018, identifying 26 peer-reviewed cohort studies comparing 1,455 children with prenatal opioid exposure to 2,982 unexposed controls across ages 6 months to 18 years. Calculated standardized mean differences using random-effects models. Subgroup analyses examined opioid type, socioeconomic controls, and assessment instruments. Prenatal opioid exposure associated with significantly lower cognitive scores at 0–2 years (d = − 0.52; 95% CI, − 0.74 to − 0.31; p < .001) and 3–6 years (d = − 0.38; 95% CI, − 0.69 to − 0.07; p < .001), corresponding to 5.7–7.8 IQ point deficits at population level. Motor scores were significantly lower (d = − 0.49; 95% CI, − 0.74 to − 0.23; p < .001). School-age group (7–18 years) showed non-significant differences (d = − 0.44; 95% CI, − 1.16 to 0.28; p = .23), though limited studies were available. Children with prenatal opioid exposure were three times more likely to have severe intellectual disability compared to general population. This study demonstrated that prenatal opioid exposure shows negative associations with neurocognitive and physical development from as early as 6 months, persisting through school age, with significant public health implications requiring long-term intervention strategies. Taghizadehghalehjoughi et al., ( 2024 ) examined fentanyl and remifentanil effects on neuron damage, oxidative stress, and cholinergic metabolism using CRL-10742 neuron cell cultures. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assays assessed cell viability. Paraoxonase 1 (PON1) activity and total thiol levels measured oxidative stress. Acetylcholinesterase and butyrylcholinesterase activities evaluated cholinergic effects. Tumor Necrosis Factor (TNF), Interleukin-8 (IL-8), and Interleukin-10 (IL-10) gene expression quantified neuroinflammation. Immunohistochemical staining with 4',6-Diamidino-2-Phenylindole (DAPI) and 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) assessed DNA damage. Highest neurotoxic dose was 10 µg/mL for both opioids, reducing neuron cell viability by 61.80% (fentanyl) and 56.89% (remifentanil). Fentanyl upregulated TNF gene expression dose-dependently, indicating neuroinflammation. Both opioids inhibited PON1 activity, suggesting increased oxidative stress. Fentanyl did not increase total thiol levels (unlike remifentanil), indicating inadequate antioxidant response. High concentrations caused DNA damage evidenced by chromatin condensation and 8-OHdG staining. This study showed fentanyl induces neurotoxicity through oxidative stress, neuroinflammation, and DNA damage pathways, with distinct mechanisms from other synthetic opioids, providing mechanistic understanding of developmental neurotoxicity. Simmons et al., ( 2023 ) conducted a research work on the Effects of prenatal opioid exposure on synaptic adaptations and behaviors across development. They analyzed synaptic plasticity mechanisms, glutamatergic and GABAergic signaling alterations, and behavioral outcomes across developmental stages. Findings indicated that prenatal opioid exposure leads to altered synaptic plasticity in cortical and limbic regions, with specific disruptions in long-term potentiation and long-term depression mechanisms. The mesolimbic dopamine pathway shows persistent dysregulation, affecting reward processing and increasing addiction vulnerability. Early life stress compounds these effects through glucocorticoid-mediated mechanisms, amplifying synaptic dysfunction in hippocampus and prefrontal cortex. Maternal separation models demonstrate that stress interacts with opioid exposure to produce greater cognitive and emotional dysregulation than either factor alone. This review established that prenatal opioid exposure produces lasting synaptic adaptations that interact with environmental stressors, creating compound vulnerabilities for neuropsychiatric disorders. The convergence of biological and environmental factors necessitates integrated intervention approaches. Olusakin et al., ( 2023 ) conducted RNA sequencing across five brain regions (nucleus accumbens [NAc], prelimbic cortex [PrL], ventral tegmental area [VTA], somatosensory cortex [S1], ventrobasal thalamus [VBT]) in perinatal fentanyl-exposed juvenile mice (postnatal day 35) of both sexes. Differential gene expression and weighted gene co-expression network analysis identified exposure-associated transcriptional programs. Findings revealed that VTA exhibited most differentially expressed genes, while robust gene enrichment occurred in NAc. Sex-specific patterns emerged: males showed pronounced mitochondrial respiration gene enrichment in NAc and VTA, plus extracellular matrix and neuronal migration pathway alterations. Females displayed vesicular cycling and synaptic signaling gene changes in NAc, plus mitochondrial respiration, synaptic, and ciliary organization alterations in sensory areas. Rank-rank hypergeometric overlap analysis revealed concordant transcriptional signatures across sexes in PrL, VTA, and S1, but discordance in NAc and VBT. This study concluded that perinatal fentanyl exposure produces distinct, region-specific, and sex-dependent transcriptomic adaptations in reward and sensory circuits. These molecular changes likely underlie structural, functional, and behavioral deficits in exposed offspring, implicating mitochondrial dysfunction and synaptic dysregulation as core mechanisms. Balalian et al., ( 2023 ) conducted a systematic review using secondary data from PubMed, Embase, PsycInfo, and Web of Science through May 2022, identifying 79 cohort and case-control studies. Newcastle-Ottawa Scale assessed quality. Studies synthesized by neurodevelopmental domain (cognitive, motor, behavioral) and assessment instrument. Heterogeneity sources systematically examined. Findings indicated significant heterogeneity existed across studies due to varying exposure ascertainment methods, pregnancy timing assessments, opioid types (non-medical, medication-assisted treatment, prescribed), co-exposures, and comparison group selection. Despite heterogeneity precluding meta-analysis, consistent negative trends emerged: cognitive skills, motor development, and behavioral regulation were generally adversely affected by prenatal opioid exposure. Medication-assisted treatment (methadone/buprenorphine) showed better outcomes than non-medical opioid use but still produced deficits compared to unexposed controls. This study concluded that while methodological diversity complicates quantitative synthesis, the weight of evidence demonstrates consistent negative associations between prenatal opioid exposure and multiple neurodevelopmental domains. Standardized assessment protocols are urgently needed to clarify dose-response relationships and optimal intervention timing. Spowart et al., ( 2023 ) conducted a prospective cohort study with third follow-up assessment of 153 children born to methadone-maintained opioid-dependent mothers (2008–2010). At ages 8–10 years, 33 traceable children (exposed group) and matched controls were assessed using Strengths and Difficulties Questionnaire (SDQ) and Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2). Regression modeling controlled for confounding factors including maternal tobacco use. Findings indicated that no group differences emerged on SDQ subscales for emotional symptoms, conduct problems, or peer relationships. However, marginally higher proportion of exposed children scored in high/very high range for hyperactivity. Critically, exposed children scored significantly higher on all BRIEF-2 indices: behavioral regulation (p < .05), emotional regulation (p < .05), cognitive regulation (p < .01), and global executive composite (p < .01). After controlling for maternal tobacco use, effect sizes reduced but remained clinically significant. This study concluded that prenatal methadone exposure is associated with specific executive function deficits in middle childhood, distinct from general behavioral problems. These findings support targeted neurodevelopmental monitoring and intervention for opioid-exposed children, with particular attention to prefrontal cortex-mediated functions. Baig et al., ( 2024 ) conducted a retrospective cohort study analyzing 94 children with documented prenatal opioid exposure evaluated with Child Behavior Checklist (CBCL) at age 2 years. Multivariable logistic regression identified factors associated with borderline/clinical range scores, including Bayley-III motor scores, discharge disposition, and neonatal opioid withdrawal syndrome treatment modalities. Findings reported that thirty children (30%) scored in borderline/clinical range on CBCL total problems, with 27% scoring borderline/clinical for externalizing problems specifically. Lower Bayley-III motor scores and discharge home with mother under safety plan were associated with borderline/clinical externalizing problems. Conversely, medication treatment for neonatal opioid withdrawal syndrome (particularly with clonidine or phenobarbital) was associated with normal-range scores across all CBCL broadband measures. This study concluded that specific clinical factors including motor development status and postnatal care arrangements predict behavioral and emotional challenges in opioid-exposed toddlers. Importantly, appropriate pharmacological management of withdrawal syndrome may have protective effects against later behavioral problems, suggesting critical intervention windows. Wen et al., ( 2021 ) conducted a retrospective cohort analysis examining prescription opioid exposure during pregnancy and subsequent neurodevelopmental disorder diagnoses in early childhood. Cumulative opioid dose and duration of exposure were quantified from prescription records. Children followed for neurodevelopmental disorder diagnoses (autism spectrum disorder, ADHD, developmental delay) using diagnostic codes. Results indicated that higher cumulative prenatal opioid doses and longer exposure durations were associated with increased neurodevelopmental disorder risk. The association was dose-dependent: higher exposures showed significant relationships with neurodevelopmental disorder risk, while lower exposures did not reach statistical significance. This pattern suggests a threshold effect or dose-response relationship between prenatal opioid exposure and adverse neurodevelopmental outcomes. This study concluded that the dose-dependent relationship between prenatal opioid exposure and neurodevelopmental disorder risk supports causal inference and informs clinical guidelines for opioid prescribing during pregnancy. Minimizing dose and duration may reduce developmental risks. Rajaprakash et al., ( 2025 ) conducted a systematic review synthesizing evidence on prenatal opioid exposure and neonatal opioid withdrawal syndrome outcomes from birth through early adulthood. Studies assessed for structural brain changes (magnetic resonance imaging/diffusion tensor imaging), cognitive outcomes, behavioral trajectories, and functional impairments across developmental stages. Findings show that prenatal opioid exposure leading to neonatal opioid withdrawal syndrome was associated with cognitive delays, language deficits, motor impairments, and higher risk for ADHD and behavioral disorders through adolescence. Structural brain alterations included white matter disruptions and altered connectivity patterns visible on neuroimaging. These effects persisted even after controlling for environmental confounders, suggesting direct biological mechanisms. Adolescents with prenatal exposure history showed increased substance use vulnerability and educational underachievement. This review concluded that prenatal opioid exposure produces a neurodevelopmental syndrome with lasting structural and functional brain changes extending into early adulthood. The persistence of deficits across decades necessitates longitudinal support systems and early intervention programs. Table 2 Summary of Empirical Studies on Fentanyl/Opioid Neurodevelopmental Effects Authors (Year) Study Type Sample/Model Key Brain Regions Primary Findings Alipio et al., ( 2021 ) Animal (Mouse) Perinatal fentanyl exposure Somatosensory cortex (S1), anterior cingulate Reduced synaptic excitation, dendritic complexity loss, altered E/I balance Yeoh et al., ( 2019 ) Meta-analysis (Human) 26 studies, 1,455 exposed children Global neurodevelopment Cognitive deficit d = − 0.52 (infancy), d = − 0.38 (preschool); motor deficit d = − 0.49 Taghizadehghalehjoughi et al., ( 2024 ) Experimental (In Vitro) Neuron cell culture (CRL-10742) Cortical/hippocampal neurons 61.8% cell death at 10µg/mL; oxidative stress, DNA damage, neuroinflammation Simmons et al., ( 2023 ) Review (Preclinical/Clinical) Synthesis of POE + ELS studies Hippocampus, limbic system, PFC Synaptic plasticity disruption; reward circuit dysregulation; stress interaction Olusakin et al., ( 2023 ) Animal (Mouse) Transcriptomic profiling NAc, VTA, PrL, S1, VBT Sex-specific gene expression changes; mitochondrial dysfunction; synaptic alterations Balalian et al., ( 2023 ) Systematic Review (Human) 79 studies Global neurodevelopment Consistent negative trends across cognitive, motor, behavioral domains Spowart et al., ( 2023 ) Clinical Cohort 33 children (ages 8–10) Executive function networks (PFC) Significant BRIEF-2 deficits in behavioral, emotional, cognitive regulation Baig et al., ( 2024 ) Retrospective Cohort 94 children (age 2) Behavioral/emotional systems 30% borderline/clinical CBCL scores; NOWS treatment protective Wen et al., ( 2021 ) Retrospective Cohort Prescription opioid exposure Global neurodevelopment Dose-dependent NDD risk; higher doses associated with increased risk Rajaprakash et al., ( 2025 ) Systematic Review (Human/Animal) Birth to early adulthood White matter, cortical, limbic Persistent structural brain changes; cognitive/behavioral deficits; ADHD risk Source: Author's Compilation (2026). 7. Research Gap and Contribution to Existing Literature 7.1 Identified Gap Despite extensive literature on fentanyl as an opioid analgesic, its abuse potential, and public health implications, a critical gap remains regarding the integration of fentanyl's specific chemical properties with neurodevelopmental mechanisms. Recent comprehensive reviews have examined various aspects of the opioid crisis, yet none have systematically connected fentanyl's molecular structure to its developmental neurotoxicity. For instance, Volkow and Blanco, ( 2021 ) examined the changing opioid crisis and neurobiological vulnerabilities but focused primarily on addiction mechanisms rather than developmental toxicology; Mattson et al., ( 2021 ) analyzed geographic and temporal trends in synthetic opioid overdose deaths without addressing chemical structure-brain development relationships; Ciccarone, ( 2021 ) characterized the "fourth wave" of the opioid crisis involving polysubstance use but did not examine molecular mechanisms of neurodevelopmental harm; O'Donnell et al., ( 2021 ) documented overdose death characteristics from illicitly manufactured fentanyls without exploring developmental exposure consequences; Hauser and Knapp, ( 2018 ) reviewed how opiate drugs disrupt neuronal and glial maturation but focused broadly on opioid class effects rather than fentanyl-specific chemistry; and Dwivedi and Haddad, ( 2024 ) investigated maternal opioid use disorder using brain organoid technology but emphasized clinical populations over chemical mechanisms. This review addresses the specific gap by systematically examining how fentanyl's phenylpiperidine structure, lipophilicity (logP ~ 4.0), and high µ-opioid receptor affinity translate into synaptic disruption, oxidative stress, and lasting cognitive-behavioral deficits when exposure occurs during critical neurodevelopmental periods. 7.2 Contribution to Existing Literature This review makes three distinct contributions: firstly, chemical-neurodevelopmental integration connecting fentanyl's verified physicochemical properties (Table 1 ) with empirical neurodevelopmental outcomes, demonstrating how molecular structure determines blood-brain barrier penetration and receptor-mediated developmental toxicity. Secondly, empirical synthesis comprehensive analysis of 10 primary empirical studies (2019–2025) specifically examining fentanyl/opioid effects on brain development, providing mechanistic insights from transcriptomics (Olusakin et al., 2023 ), electrophysiology (Alipio et al., 2021 ), and clinical neuropsychology (Spowart et al., 2023 ). Lastly, translational framework evidence-based foundation for chemistry-informed interventions, connecting computational molecular dynamics research with public health prevention strategies aligned with Sustainable Development Goal 3.5. 8. Future Research Directions Future research must prioritize computational chemistry and structure-based drug design to address fentanyl's neurodevelopmental toxicity. Recent molecular dynamics studies have elucidated critical binding mechanisms that inform safer analog development. 8.1 Computational Chemistry Approaches Molecular Dynamics Insights Research utilizing X-ray crystallography of the µ-opioid receptor in complex with fentanyl has identified detailed interaction profiles, providing structural bases for binding affinity and abuse potential (Vo et al., 2021 ). Studies have employed weighted ensemble molecular dynamics and metadynamics simulations to characterize fentanyl's dual binding modes at µ-opioid receptor involving both the canonical Asp3.32 salt bridge and a secondary His6.52 hydrogen bonding configuration (Xie et al., 2022 ). Key Finding Fentanyl's unique ability to adopt a "deep binding" mode through hydrogen bonding with His297 (when protonated at Nδ) creates prolonged receptor residence times nearly 1–2 orders of magnitude longer than alternative protonation states. This molecular mechanism explains fentanyl's exceptional potency and suggests that modifying the piperidine nitrogen interaction profile could reduce both analgesic efficacy and developmental toxicity. 8.2 Structure-Based Design of Safer Analogs Research demonstrates that fentanyl analogs with modified N-chain volumes and anilide aromatic ring substitutions show nonlinear structure-activity relationships (Vardanyan & Hruby, 2014 ; Lipiński et al., 2019 ). Optimal binding affinity occurs with medium-sized substituents, while both smaller and larger modifications reduce potency. Future Direction : Computational screening of fentanyl derivatives with: (1) Modified piperidine substitutions reducing His6.52 binding mode stability; (2) Altered lipophilicity (reducing logP below 4.0) to slow blood-brain barrier penetration during developmental exposure; (3) Enhanced plasma protein binding to reduce free drug concentration available for central nervous system entry. 8.3 Neuroprotective Chemistry Strategies Building upon Taghizadehghalehjoughi et al.'s ( 2024 ) findings regarding oxidative stress pathways, future research should investigate: Antioxidant co-formulations combining fentanyl with thiol-replenishing agents (as remifentanil naturally increases total thiol levels); Pro-drug approaches developing esterase-activated fentanyl pro-drugs requiring metabolic conversion, thereby reducing acute central nervous system exposure peaks during accidental ingestion; and Receptor-selective analogs exploiting computational models to design µ-opioid receptor agonists with reduced β-arrestin recruitment (biased agonism), potentially preserving analgesia while minimizing receptor internalization and developmental signaling disruption. 8.4 Public Awareness and Chemistry Education The devastating neurodevelopmental effects documented in this review particularly the 30% rate of clinical-range behavioral problems in exposed toddlers (Baig et al., 2024 ) and persistent executive deficits through age 10 (Spowart et al., 2023 ) demand enhanced public awareness campaigns. Chemistry education should emphasize: structural features enabling rapid central nervous system penetration (lipophilicity, small molecular weight); dose-response relationships showing no "safe" exposure level during pregnancy; and mechanisms of placental transfer and fetal brain vulnerability. 9. Conclusion This systematic review examined the chemistry of fentanyl and its implications for brain development through integration of molecular pharmacology and empirical neurodevelopmental research. Key findings demonstrate that fentanyl's phenylpiperidine structure (C₂₂H₂₈N₂O), exceptional lipophilicity (logP ~ 4.0), and high µ-opioid receptor affinity create unique risks for developmental neurotoxicity when exposure occurs during critical periods. Methodologically, this review synthesized 10 PRISMA-selected studies (2018–2025) employing diverse approaches: preclinical electrophysiology and transcriptomics (Alipio et al., 2021 ; Olusakin et al., 2023 ), clinical neuropsychological assessment (Spowart et al., 2023 ; Baig et al., 2024 ), systematic meta-analyses (Yeoh et al., 2019 ; Balalian et al., 2023 ), and in vitro neurotoxicity assays (Taghizadehghalehjoughi et al., 2024 ). This methodological diversity strengthens confidence in convergent findings while highlighting heterogeneity requiring standardized future research. The findings of this research establish that perinatal fentanyl exposure produces: (1) lasting somatosensory circuit dysfunction through altered excitation-inhibition balance; (2) sex-specific transcriptomic alterations in reward regions involving mitochondrial dysfunction and synaptic dysregulation; (3) dose-dependent cognitive and motor deficits equivalent to 5.7–7.8 IQ point reductions; (4) executive function impairments persisting to middle childhood; and (5) structural brain changes visible through adolescence. Mechanistically, these effects derive from fentanyl's rapid blood-brain barrier penetration, oxidative stress induction, DNA damage, and disruption of neurotransmitter homeostasis during synaptogenesis and myelination. This review advances Sustainable Development Goal 3 (Target 3.5) by providing an evidence base for reducing substance-related harm through chemistry-informed prevention, and contributes to Sustainable Development Goal 4.7 by integrating health risk knowledge into scientific education. The chemistry-brain development framework established here offers a template for investigating neurodevelopmental risks of emerging synthetic opioids and designing molecular interventions to protect vulnerable developing brains. Recommendations Clinical : Implement mandatory neurodevelopmental screening for all opioid-exposed children from infancy through adolescence. Regulatory : Restrict fentanyl prescribing during pregnancy to cases where alternatives are contraindicated, with mandatory neonatal follow-up protocols. Research : Prioritize computational chemistry studies elucidating structure-neurotoxicity relationships to guide safer analog design. Public Health : Deploy chemistry-informed awareness campaigns emphasizing fentanyl's unique developmental risks compared to other opioids. Harm Reduction : Expand access to medication-assisted treatment (methadone/buprenorphine) which shows better neurodevelopmental outcomes than non-medical opioid use, while ensuring long-term developmental monitoring. References Alipio JB, Haga C, Fox ME, Arakawa K, Balaji R, Cramer N, Lobo MK, Keller A (2021) Perinatal fentanyl exposure leads to long-lasting impairments in somatosensory circuit function and behavior. J Neurosci 41(15):3400–3417. https://doi.org/10.1523/JNEUROSCI.2470-20.2020 Alzu'bi A, Baker B, Al-Trad W, Zoubi BA, AbuAlArjah MS, Abu-El-Rub MI, Tahat E, Helaly L, Ghorab AMNZ, El-Huneidi DS, W. and, Al-Zoubi RM (2024) The impact of chronic fentanyl administration on the cerebral cortex in mice: Molecular and histological effects. Brain Res Bull 209:110917. https://doi.org/10.1016/j.brainresbull.2024.110917 Armenian P, Vo KT, Barr-Walker J, Lynch KL (2018) 'Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review', Neuropharmacology , 134(Pt A), pp. 121–132. https://doi.org/10.1016/j.neuropharm.2017.10.016 Baig N, Sun Q, Liu C, Ehrlich S, Merhar S, McAllister J (2024) Neurobehavioral problems at age 2 years in children with prenatal opioid exposure. J Perinatol 44(8):1146–1151. https://doi.org/10.1038/s41372-024-01913-7 Balalian AA, Graeve R, Richter M, Fink A, Kielstein H, Martins SS, Philbin MM, Factor-Litvak P (2023) Prenatal exposure to opioids and neurodevelopment in infancy and childhood: A systematic review. Front Pead 11:1071889. https://doi.org/10.3389/fped.2023.1071889 Barletta C, Di Natale V, Esposito M, Chisari M, Cocimano G, Di Mauro L, Salerno M, Sessa F (2025) The rise of fentanyl: Molecular aspects and forensic investigations. Int J Mol Sci 26(2):444. https://doi.org/10.3390/ijms26020444 Bierce L, Tabachnick AR, Eiden RD, Dozier M, Labella M (2023) A 12-month follow-up of infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use. Neurotoxicol Teratol 97:107176. https://doi.org/10.1016/j.ntt.2023.107176 Castro EM, Lotfipour S, Leslie FM (2023) Nicotine on the developing brain. Pharmacol Res 190:106716. https://doi.org/10.1016/j.phrs.2023.106716 Centers for Disease Control and Prevention (CDC) (2025) Understanding the opioid overdose epidemic . Available at: https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html Ciccarone D (2021) The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry 34(4):344–350. https://doi.org/10.1097/YCO.0000000000000717 Clinton HA, Thangada S, Gill JR, Mirizzi A, Logan SB (2021) Improvements in toxicology testing to identify fentanyl analogs and other novel synthetic opioids in fatal drug overdoses, Connecticut, January 2016–June 2019. Public Health Rep 136(1 suppl):80S–86S. https://doi.org/10.1177/00333549211042829 Davis MP, Behm B (2020) Reasons to avoid fentanyl. Annals Palliat Med 9(2):410–418. https://doi.org/10.21037/apm.2020.01.12 Dong T, Lei S, Ding G (2025) Comparative effectiveness of propofol-sufentanil vs propofol-fentanyl in elderly patients undergoing transurethral resection of the prostate. Ther Clin Risk Manag 21:1773–1782. https://doi.org/10.2147/TCRM.S549323 Dwivedi I, Haddad GG (2024) Investigating the neurobiology of maternal opioid use disorder and prenatal opioid exposure using brain organoid technology. Front Cell Neurosci 18:1403326. https://doi.org/10.3389/fncel.2024.1403326 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2025) Fentanyl drug profile . Available at: https://www.euda.europa.eu/publications/drug-profiles/fentanyl_en Financial Action Task Force (FATF) (2022) Money laundering from fentanyl and synthetic opioids . Paris: FATF. Available at: https://www.fatf-gafi.org/publications/methodsandtrends/documents/money-laundering-fentanyl-syntheticopioids.html Friedman JR, Romero R, Funnell A, Goodman-Meza D, Shover CL (2025) What does polysubstance really mean? Comparing drug-involved deaths in CDC records vs. detailed medical examiner data from Los Angeles. Int J Drug Policy 148:105129. https://doi.org/10.1016/j.drugpo.2025.105129 Han Y, Cao L, Yuan K et al (2022) Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse. Neurosci Bull 38:1365–1382. https://doi.org/10.1007/s12264-022-00872-3 Hauser KF, Knapp PE (2018) Opiate drugs with abuse liability hijack the endogenous opioid system to disrupt neuronal and glial maturation in the central nervous system. Front Pead 5:294. https://doi.org/10.3389/fped.2017.00294 Henthorn TK, Mikulich-Gilbertson SK (2018) µ-Opioid receptor agonists: Do they have utility in the treatment of acute pain? Anesthesiology 128(5):867–870. https://doi.org/10.1097/ALN.0000000000002126 Hussien RM, Rabie AH (2019) Sequential intrathecal injection of fentanyl and hyperbaric bupivacaine at different rates: Does it make a difference? A randomized controlled trial. Korean J Anesthesiology 72(2):150–155. https://doi.org/10.4097/kja.d.18.00173 Jaekel J, Kim HM, Lee SJ, Schwartz A, Henderson JMT, Woodward LJ (2021) Emotional and behavioral trajectories of 2 to 9 years old children born to opioid-dependent mothers. Res Child Adolesc Psychopathol 49(4):443–457. https://doi.org/10.1007/s10802-020-00766-w Jalali MS, Botticelli M, Hwang RC (2020) The opioid crisis: A contextual, social-ecological framework. Health Res Policy Syst 18:87. https://doi.org/10.1186/s12961-020-00596-8 Jelínková R (2024) Fentanyl and its derivatives: Pharmacology, use and abuse, and detection possibilities. Contemporary Topics in Patient Safety, vol 3. IntechOpen, London. https://doi.org/10.5772/intechopen.113090 Jiang W, Merhar SL, Zeng Z, Zhu Z, Yin W, Zhou Z, Wang L, He L, Vannest J, Lin W (2022) Neural alterations in opioid-exposed infants revealed by edge-centric brain functional networks. Brain Commun 4(3):fcac112. https://doi.org/10.1093/braincomms/fcac112 Karatayev O, Collier AD, Targoff SR, Leibowitz SF (2024) Neurological disorders induced by drug use: Effects of adolescent and embryonic drug exposure on behavioral neurodevelopment. Int J Mol Sci 25(15):8341. https://doi.org/10.3390/ijms25158341 Larnder A, Saatchi A, Borden SA, Moa B, Gill CG, Wallace B, Hore D (2022) Variability in the unregulated opioid market in the context of extreme rates of overdose. Drug Alcohol Depend 235:109427. https://doi.org/10.1016/j.drugalcdep.2022.109427 Leppert W, Malec-Milewska M, Zajaczkowska R, Wordliczek J (2018) Transdermal and topical drug administration in the treatment of pain. Molecules 23(3):681. https://doi.org/10.3390/molecules23030681 Lipiński PFJ, Jarończyk M, Dobrowolski JC, Sadlej J (2019) Molecular dynamics of fentanyl bound to µ-opioid receptor. J Mol Model 25(5):144. https://doi.org/10.1007/s00894-019-3999-2 Manuel JI, Baslock D, DeBarros T, Halliday T, Pietruszewski P, Plante A, Woods Razaa J, Sloyer W, Stanhope V (2023) Factors associated with indirect exposure to and knowledge of fentanyl among youth. J Adolesc Health 74(2):191–198. https://doi.org/10.1016/j.jadohealth.2023.08.040 Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL (2021) 'Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019', MMWR Morbidity and Mortality Weekly Report , 70, pp. 202–207. https://doi.org/10.15585/mmwr.mm7006a4 National Center for Biotechnology Information (2026) PubChem compound summary for CID 3345, fentanyl . Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Fentanyl O'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J (2021) 'Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls — United States, 2019–2020', MMWR Morbidity and Mortality Weekly Report , 70, pp. 1740–1746. https://doi.org/10.15585/mmwr.mm7050e3 Olusakin J, Kumar G, Basu M, Calarco CA, Fox ME, Alipio JB, Haga C, Turner MD, Keller A, Ament SA, Lobo MK (2023) Transcriptomic profiling of reward and sensory brain areas in perinatal fentanyl exposed juvenile mice. Neuropsychopharmacology 48(12):1724–1734. https://doi.org/10.1038/s41386-023-01639-8 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D (2021) 'The PRISMA 2020 statement: An updated guideline for reporting systematic reviews', BMJ , 372, p. n71. https://doi.org/10.1136/bmj.n71 Pickens CM, Park J, Casillas SM, Smith K, Hoots BE, Vivolo-Kantor AM, O'Donnell J (2025) Trends in suspected fentanyl-involved nonfatal overdose emergency department visits, by age group, sex, and race and ethnicity — United States, October 2020–March 2024. MMWR Morbidity Mortal Wkly Rep 74(16):282–287. https://doi.org/10.15585/mmwr.mm7416a2 Posa F, Porfilio A (2025) A review on fentanyl and the neuroscientific roots of criminal behaviour: Forensic and legal reflections. Med Res Archives 13(11). https://doi.org/10.18103/mra.v13i11.0000 Rajaprakash M, West S, Jayakumar S, Robinson J, Burton VJ, Gerner G (2025) 'Neurodevelopmental outcomes of prenatal opioid exposure and neonatal opioid withdrawal syndrome: A systematic review from birth to early adulthood', Journal of Perinatology . Available at: https://doi.org/10.1038/s41372-025-02496-7 Ramos-Matos CF, Bistas KG, Lopez-Ojeda W (2023) 'Fentanyl', in StatPearls . Treasure Island, FL: StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459275/ Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G (2018) Drug and opioid-involved overdose deaths — United States, 2013–2017. MMWR Morbidity Mortal Wkly Rep 67(51–52):1419–1427. https://doi.org/10.15585/mmwr.mm675152e1 Simmons SC, Grecco GG, Atwood BK, Nugent FS (2023) 'Effects of prenatal opioid exposure on synaptic adaptations and behaviors across development', Neuropharmacology , 222, p. 109312. https://doi.org/10.1016/j.neuropharm.2022.109312 Spowart KM, Reilly K, Mactier H, Hamilton R (2023) Executive functioning, behavioural, emotional, and cognitive difficulties in school-aged children prenatally exposed to methadone. Front Pead 11:1118634. https://doi.org/10.3389/fped.2023.1118634 Stanley TH (2014) The fentanyl story. J Pain 15(12):1215–1226. https://doi.org/10.1016/j.jpain.2014.08.010 Steinfeld MR, Torregrossa MM (2023) Consequences of adolescent drug use. Translational Psychiatry 13:313. https://doi.org/10.1038/s41398-023-02590-4 Taghizadehghalehjoughi A, Naldan ME, Yeni Y, Genc S, Hacimuftuoglu A, Isik M, Necip A, Bolat İ, Yildirim S, Beydemir S, Baykan M (2024) Effect of fentanyl and remifentanil on neuron damage and oxidative stress during induction neurotoxicity. J Cell Mol Med 28(4):e18118. https://doi.org/10.1111/jcmm.18118 Vardanyan RS, Hruby VJ (2014) Fentanyl-related compounds and derivatives: Current status and future prospects for pharmaceutical applications. Future Med Chem 6(4):385–412. https://doi.org/10.4155/fmc.13.215 Vo QN, Mahinthichaichan P, Shen J, Ellis CR, Zhang S, Gross ML, Liu J (2021) How µ-opioid receptor recognizes fentanyl. Nat Commun 12:984. https://doi.org/10.1038/s41467-021-21262-9 Volkow ND, Blanco C (2021) The changing opioid crisis: Development, challenges and opportunities. Mol Psychiatry 26(1):218–233. https://doi.org/10.1038/s41380-020-0661-4 Wen X, Lawal OD, Belviso N, Matson KL, Wang S, Quilliam BJ, Meador KJ (2021) Association between prenatal opioid exposure and neurodevelopmental outcomes in early childhood: A retrospective cohort study. Drug Saf 44(8):863–875. https://doi.org/10.1007/s40264-021-01080-0 Wilde M, Pichini S, Pacifici R, Tagliabracci A, Busardò FP, Auwärter V, Solimini R (2019) Metabolic pathways and potencies of new fentanyl analogs. Front Pharmacol 10:238. https://doi.org/10.3389/fphar.2019.00238 Williamson J, Kermanizadeh A (2024) A review of toxicological profile of fentanyl — a 2024 update. Toxics 12(10):690. https://doi.org/10.3390/toxics12100690 World Health Organization (WHO) (2025) Opioid overdose: Fact sheet . Available at: https://www.who.int/news-room/fact-sheets/detail/opioid-overdose Xie B, Goldberg A, Shi L (2022) A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the µ-opioid receptor. Comput Struct Biotechnol J 20:2309–2321. https://doi.org/10.1016/j.csbj.2022.05.013 Yeoh SL, Eastwood J, Wright IM, Morton R, Melhuish E, Ward M, Oei JL (2019) Cognitive and motor outcomes of children with prenatal opioid exposure: A systematic review and meta-analysis. JAMA Netw Open 2(7):e197025. https://doi.org/10.1001/jamanetworkopen.2019.7025 Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-9288777","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":615770539,"identity":"802d5efd-36f8-447a-8750-3c54baa7ea04","order_by":0,"name":"Alli, A. O.","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7ElEQVRIiWNgGAWjYDACduaGA0AqgYGBsfEBkMHDR1ALMyNcS7MBSAsbMVoYIFoY2CRALIJa+JsZGw/8bLPJ4592uK3ya46dDBsD88NHN/BokTjM2HCwty2tWOJ2Yttt2W3JQIexGRvn4LMGqOUAb9vhxAaQFsltzEAtPGzS+LTIg2z5C9QyH6ilWHJbPWEtBkAth0G2bABqYfy47TBhLYYgLTLn0ooNbyc2SzNuO87DxkzAL3LHmw9/fFNmkyd3O/3hx5/bqu352ZsfPsbrfRBghMYFMw+YJKQcDP5Atf4gSvUoGAWjYBSMNAAATMtNqJUOcjwAAAAASUVORK5CYII=","orcid":"https://orcid.org/0009-0002-8390-9406","institution":"Federal College of Education, Abeokuta","correspondingAuthor":true,"prefix":"","firstName":"A.","middleName":"O.","lastName":"Alli","suffix":""}],"badges":[],"createdAt":"2026-04-01 08:18:49","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-9288777/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-9288777/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":106070712,"identity":"fc20cc46-517a-46a9-90c0-5aa579951409","added_by":"auto","created_at":"2026-04-03 06:29:48","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":57498,"visible":true,"origin":"","legend":"\u003cp\u003ePRISMA 2020 flow diagram showing study selection process for this systematic review.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-9288777/v1/1dd4b6cd1cbc1694ba571551.png"},{"id":106070711,"identity":"642a9c99-bc3d-4261-8c02-a6e3ce988e98","added_by":"auto","created_at":"2026-04-03 06:29:48","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":20487,"visible":true,"origin":"","legend":"\u003cp\u003eChemical structure of fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide).\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-9288777/v1/1e978fda983ee7c9542e1487.png"},{"id":106094509,"identity":"357b7882-6496-47df-882b-ed2def8edaf0","added_by":"auto","created_at":"2026-04-03 11:42:47","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1113549,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-9288777/v1/88fee9ba-9796-4ad4-9106-37ff2ebd9737.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eThe Chemistry of Fentanyl and Its Implications on Brain Development: A Review\u003c/p\u003e","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eOver the past 20 years, opioid misuse has become a major public health issue worldwide. Both medical and non-medical uses have contributed to rising addiction and overdoses (Jalali, 2020; World Health Organization (WHO), \u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). Initially, prescription opioids, such as oxycodone, drove the epidemic, but illicit opioids subsequently became dominant, particularly in North America and Europe (Centers for Disease Control and Prevention (CDC), \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). Volkow and Blanco (\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) indicated that synthetic opioids, especially fentanyl and its analogs, now drive this stage of the epidemic (Mattson et al., \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). These substances are widely available in illegal markets, often mixed with other drugs without the user\u0026rsquo;s knowledge, creating unpredictable overdose risks (O'Donnell et al., \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Friedman et al. (\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e2025\u003c/span\u003e) characterized this as a \"fourth wave\" involving polysubstance use (Ciccarone, \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Despite extensive research on mortality, the biological consequences of fentanyl exposure remain less explored, particularly regarding brain development (Alzu'bi et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Hauser \u0026amp; Knapp, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Dwivedi \u0026amp; Haddad, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Posa \u0026amp; Porfilio, \u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e2025\u003c/span\u003e; Williamson \u0026amp; Kermanizadeh, \u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Exposure among vulnerable groups, including adolescents and those with early life exposure, appears to be increasing (Alipio et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Manuel et al., \u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Olusakin et al., \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Pickens et al., \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e2025\u003c/span\u003e). This review addresses this gap by examining the association between fentanyl exposure and brain development, integrating chemistry, pharmacology, and neuroscience. This approach contributes to Sustainable Development Goal 3, Target 3.5, by informing harm-reduction strategies and supports Sustainable Development Goal 4 by increasing health risk awareness.\u003c/p\u003e \u003cdiv id=\"Sec2\" class=\"Section2\"\u003e \u003ch2\u003e1.1 Fentanyl as a Synthetic Opioid\u003c/h2\u003e \u003cp\u003eFentanyl is a fully synthetic phenylpiperidine opioid widely used for anesthesia and severe pain management purposes. Its effects are rapid and potent when administered under medical supervision (Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e). Its high potency is derived from strong \u0026micro;-opioid receptor binding, which also produces respiratory depression risk, even at moderate doses. Its lipophilic properties enable rapid blood-brain barrier crossing, explaining its rapid central nervous system effects (Han et al., \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). These features create medical utility but also pose a high risk. Illicitly manufactured fentanyl is increasingly appearing in drug markets, sometimes mixed unknowingly with other substances, creating uncertainty about its composition and strength (Volkow \u0026amp; Blanco, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Mattson et al., \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). This unpredictability increases the risk of overdose and may explain the rising mortality (O'Donnell et al., \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Although the pharmacological effects have been documented, the implications for brain development remain unclear. This review bridges this gap by connecting the chemical and pharmacokinetic properties of these chemicals with neurodevelopmental processes.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e1.2 Importance of Studying Brain Development Effects\u003c/h2\u003e \u003cp\u003eUnderstanding the effects of fentanyl on brain development is critical because the developing nervous system is highly sensitive to chemical influences. During the critical period of prenatal stages and adolescence, the brain undergoes neurogenesis, synaptogenesis, synaptic pruning, and myelination, which are necessary for functional neural circuits (Hauser \u0026amp; Knapp, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Dwivedi \u0026amp; Haddad, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Disruption by potent opioids can produce lasting effects in adulthood. Fentanyl's lipophilicity and strong \u0026micro;-opioid receptor affinity allow rapid central nervous system entry, interfering with neurotransmission and signaling pathways that guide neural maturation (Han et al., \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e). Animal studies suggest that early life exposure disrupts synaptic development, changes gene expression, and alters neural circuit formation (Alipio et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Olusakin et al., \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Human studies have linked prenatal opioid exposure to cognitive difficulties, behavioral problems, and delayed developmental milestones (Yeoh et al., \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Balalian et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). These risks are particularly concerning given the prevalence of fentanyl in illicit markets, where exposure may occur unknowingly with widely varying doses (Mattson et al., \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; O'Donnell et al., \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Understanding how the chemical properties of fentanyl translate into developmental outcomes is essential for guiding clinical practice, informing public health interventions, and supporting harm reduction policies aligned with Sustainable Development Goal 3, Target 3.5.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e1.3 Research Objectives and Scope\u003c/h2\u003e \u003cp\u003eThis review examines the chemistry of fentanyl and its implications for brain development through (i) analysis of the molecular structure and physicochemical properties influencing pharmacokinetics and pharmacodynamics; (ii) exploration of central nervous system interactions, particularly through \u0026micro;-opioid receptors; and (iii) review of neurodevelopmental outcomes from exposure during sensitive periods, including prenatal development and adolescence. The review draws primarily on studies from 2018 to 2025 for recent pharmacological and developmental evidence, with older studies included where relevant. Both preclinical and clinical studies are considered to provide comprehensive developmental-stage coverage.\u003c/p\u003e \u003c/div\u003e"},{"header":"2. Methodology","content":"\u003cp\u003eThis systematic review followed the PRISMA 2020 guidelines (Page et al., \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) to ensure methodological clarity and reproducibility. Searches were conducted in PubMed, Scopus, Web of Science, and Embase using combinations of terms: \"fentanyl,\" \"synthetic opioids,\" \"brain development,\" \"neurodevelopment,\" \"\u0026micro;-opioid receptor,\" \"blood-brain barrier,\" \"prenatal exposure,\" and \"adolescent brain.\" Boolean operators (AND, OR) were used to identify relevant studies. The search strategy was designed to identify peer-reviewed articles examining the chemical, pharmacological, or neurodevelopmental effects of fentanyl in humans, animals, or in vitro models.\u003c/p\u003e \u003cp\u003eThis review considered studies published between 2018 and 2025. The inclusion criteria were as follows: (1) examination of fentanyl or fentanyl analogs; (2) focus on brain development, neurodevelopment, or neurotoxicity; (3) empirical data from experimental, clinical, or epidemiological studies; and (4) peer-reviewed publication in English. The exclusion criteria eliminated editorials, commentaries, non-peer-reviewed sources, conference abstracts, duplicates, and studies not directly related to brain development or lacking fentanyl-specific data.\u003c/p\u003e \u003cp\u003eAfter duplicate removal, the titles and abstracts were screened independently by two reviewers. Full texts were reviewed to confirm eligibility, and borderline cases were resolved through discussion and consensus. Data extraction captured the study design, sample characteristics, opioid exposure type, main findings, and quality indicators. The risk of bias was assessed using appropriate tools: SYRCLE for animal studies, the Newcastle-Ottawa Scale for observational studies, and Cochrane tools for clinical trials. The evidence was grouped into four themes: early life exposure, neuronal and synaptic changes, cognitive outcomes, and public health implications.\u003c/p\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.1 PRISMA 2020 Flow Diagram\u003c/h2\u003e \u003c/div\u003e"},{"header":"3. History of Fentanyl: Development and Implications","content":"\u003cp\u003eFentanyl was first synthesized in 1960 by Dr. Paul Janssen, a Belgian physician and medicinal chemist at Janssen Pharmaceutica in Beerse, Belgium (Barletta et al., \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2025\u003c/span\u003e; Stanley, \u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e2014\u003c/span\u003e). Janssen developed fentanyl as part of a systematic research investigating phenylpiperidine derivatives with enhanced analgesic properties compared to existing opioids. The compound was designed for rapid onset and short duration characteristics, which are desirable for surgical anesthesia. It was clinically approved in 1963 in Western Europe, and entered the U.S. market in 1968 under the brand name Sublimaze (combined with droperidol as Innovar) (Jel\u0026iacute;nkov\u0026aacute;, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Subsequent standalone approvals were made in 1972. The transdermal patch (Duragesic) developed in the mid-1990s expanded applications to chronic pain management, while oral formulations, including Actiq and Onsolis, provided alternative delivery mechanisms (Leppert et al., \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e2018\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003e3.1 Clinical Advantages and Neurodevelopmental Disadvantages\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eClinical Advantages\u003c/strong\u003e \u003cp\u003eRapid blood-brain barrier penetration enables effective anesthesia with minimal cardiovascular depression. Short durations reduce prolonged central nervous system depression in surgical contexts. Transdermal delivery provides controlled dosing for chronic pain without repeated central nervous system activation (Davis \u0026amp; Behm, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2020\u003c/span\u003e; Dong et al., \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e2025\u003c/span\u003e; Henthorn \u0026amp; Mikulich-Gilbertson, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Hussien \u0026amp; Rabie, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Ramos-Matos et al., \u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e2023\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eNeurodevelopmental Disadvantages\u003c/strong\u003e \u003cp\u003eExtreme potency (50\u0026ndash;100\u0026times; morphine) creates a narrow therapeutic index, increasing the risk of hypoxic brain injury during overdose. High lipophilicity (logP\u0026thinsp;~\u0026thinsp;4.0) facilitates rapid entry into the central nervous system, overwhelming the developing neural circuits. Strong \u0026micro;-opioid receptor affinity disrupts neurotransmitter homeostasis, which is critical for synaptogenesis and myelination. Illicit manufacturing variability creates unpredictable exposure levels, which are particularly dangerous during pregnancy (Davis \u0026amp; Behm, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2020\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e"},{"header":"4. Chemistry of Fentanyl: Physical and Chemical Properties","content":" \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePhysicochemical Properties of Fentanyl\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eProperty\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eValue/Description\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSignificance for Brain Development\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIUPAC Name\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eN-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDefines molecular scaffold for structure-activity relationships\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMolecular Formula\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eC₂₂H₂₈N₂O\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePhenylpiperidine class distinguishes from morphinan opioids\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMolecular Weight\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e336.471 g/mol\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAffects transport kinetics across biological membranes\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eChemical Class\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSynthetic phenylpiperidine opioid\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eEnables complete chemical synthesis (unlike plant-derived morphine)\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLogP (Lipophilicity)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e~\u0026thinsp;4.0 (highly lipophilic)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRapid blood-brain barrier penetration; accumulates in lipid-rich neural tissue\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAqueous Solubility\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSlightly soluble\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLimits intravenous formulation options; favors lipid-based delivery\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epKa\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e8.99 (tertiary amine)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eIonization state affects \u0026micro;-opioid receptor binding affinity at physiological pH\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMelting Point\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e87\u0026ndash;88\u0026deg;C\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePhysical stability affects formulation and illicit manufacturing\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePrimary Functional Groups\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTertiary amine (piperidine), aromatic phenyl rings, amide linkage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTertiary amine forms ionic bond with Asp3.32 of \u0026micro;-opioid receptor; aromatic rings enable hydrophobic interactions\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eVolume of Distribution\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLarge (4\u0026ndash;6 L/kg)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eExtensive tissue distribution including brain, lungs, adipose tissue\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlasma Protein Binding\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e80\u0026ndash;85%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAffects free drug concentration available for central nervous system entry\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMetabolism\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHepatic CYP3A4 \u0026rarr; norfentanyl\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eVariable metabolic rates affect duration of central nervous system exposure\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eElimination Half-life\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u0026ndash;12 hours (context-dependent)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eProlonged exposure in neonates due to immature clearance systems\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePotency Relative to Morphine\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e50\u0026ndash;100 times more potent\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSmall dosing errors produce catastrophic central nervous system depression\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eTable\u0026nbsp;1_Source: Compiled from\u003c/em\u003e National Center for Biotechnology Information (\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e2026\u003c/span\u003e\u003cem\u003e), European Monitoring Centre for Drugs and Drug Addiction (2025)\u003c/em\u003e, Han et al. (\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e), \u003cem\u003eand\u003c/em\u003e Armenian et al. (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e4.1 Molecular Structure and Functional Groups\u003c/h2\u003e \u003cp\u003eThe chemical structure of fentanyl features a central piperidine ring with an anilide group at the 4-position and a phenethyl side chain. This arrangement provides a flexible three-dimensional shape that facilitates biological target interactions. Aromatic rings and amide linkages enhance receptor-binding strength and chemical stability (Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cb\u003eKey functional groups include\u003c/b\u003e:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eTertiary amine\u003c/b\u003e: Interacts ionically with \u0026micro;-opioid receptors (specifically Asp3.32 residue)\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eAromatic phenyl rings\u003c/b\u003e: Enable hydrophobic interactions in the receptor binding site\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eAmide linkage (-CONH-)\u003c/b\u003e: Contributes to molecular stability and receptor affinity together, these features explain fentanyl's strong \u0026micro;-opioid receptor affinity, related to both analgesic and psychoactive effects, and its exceptional potency compared to morphine.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e4.2 Synthetic Pathways and Analogues\u003c/h2\u003e \u003cp\u003eFentanyl's synthetic origin allows for controlled pharmaceutical production but also enables unregulated manufacturing (Larnder et al., \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Financial Action Task Force [FATF], 2022). The phenylpiperidine structure permits modifications at multiple chemical positions, producing numerous analogs with varying pharmacological properties (Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e). Structural changes, although sometimes small at the molecular level, can produce dramatically different effects on potency, receptor binding, and duration. Some analogs exceed the potency of fentanyl, increasing the risk of overdose at very low concentrations. These analogs create unpredictability in illicit supplies, with users often unaware of the composition or concentration, complicating detection and clinical management (Clinton et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2021\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003e4.3 Pharmacokinetics (ADME)\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eAbsorption\u003c/strong\u003e \u003cp\u003eHigh lipophilicity enables rapid absorption through intravenous, transdermal, and transmucosal routes, with quick blood-brain barrier crossing (Han et al., \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Taghizadehghalehjoughi et al., \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eDistribution\u003c/strong\u003e \u003cp\u003eFentanyl distributes widely into highly perfused tissues and lipid-rich areas including brain, lungs, and adipose tissue, reflecting large volume of distribution (4\u0026ndash;6 L/kg). This supports strong central effects but creates unpredictability, with potential accumulation during repeated exposure (Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eMetabolism\u003c/strong\u003e \u003cp\u003eHepatic CYP3A4 metabolism produces norfentanyl. Individual genetic and physiological differences influence metabolic rates, affecting duration and intensity of effects (Wilde et al., \u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e2019\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eElimination\u003c/strong\u003e \u003cp\u003ePrimarily renal, though clearance varies with metabolic capacity and usage patterns. These features rapid absorption, wide distribution, and variable metabolism explain fentanyl's potency while narrowing the margin between therapeutic and toxic doses (Barletta et al., \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2025\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003e4.4 Pharmacodynamics\u003c/h2\u003e \u003cp\u003eFentanyl primarily exerts its effects through \u0026micro;-opioid receptor activation. \u0026micro;-Opioid receptors are distributed throughout the central nervous system, particularly in areas associated with pain, reward, and autonomic control. Binding triggers intracellular changes, such as reduced adenylate cyclase activity, decreased cyclic AMP levels, and altered ion channel function (reduced calcium influx and increased potassium efflux), resulting in reduced neuronal activity and neurotransmitter release (Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Han et al., \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Taghizadehghalehjoughi et al., \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). This explains the analgesic and sedative effects but also disrupts normal synaptic processes, particularly consequential during brain development, where timing and signaling are critical (Hauser \u0026amp; Knapp, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2018\u003c/span\u003e). These effects extend beyond pain relief to euphoria, sedation, and respiratory depression. Brainstem \u0026micro;-opioid receptor activation reduces respiratory drive, explaining the high overdose risk (Han et al., \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Taghizadehghalehjoughi et al., \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Simultaneously, fentanyl affects reward systems through mesolimbic pathway influence, increasing dopamine via GABAergic interneuron inhibition in the nucleus accumbens, which is associated with reinforcement and dependence (Volkow \u0026amp; Blanco, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Mattson et al., \u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Its potency (50\u0026ndash;100\u0026times; morphine) is related to strong receptor binding and rapid central nervous system entry (Armenian et al., \u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e2018\u003c/span\u003e), creating small margins between therapeutic and harmful doses. Repeated exposure produces tolerance through receptor downregulation and changes in intracellular signaling pathways (Hauser \u0026amp; Knapp, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2018\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e"},{"header":"5. Implications of Fentanyl on Brain Development","content":"\u003cp\u003eFentanyl exposure disrupts brain development during sensitive periods when neural systems are particularly vulnerable (Castro et al., \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Karatayev et al., \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Steinfeld \u0026amp; Torregrossa, \u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Prenatal development represents the earliest and most vulnerable stage, involving neurogenesis, neuronal migration, and early circuit formation. Perinatal fentanyl exposure affects somatosensory circuit development and produces long-term behavioral changes (Alipio et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Transcriptomic studies report gene expression changes in reward and sensory processing pathways (Olusakin et al., \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), indicating early neural organization disruptions in somatosensory cortex and nucleus accumbens. The early postnatal period (infancy through early childhood) involves rapid synaptic pruning, myelination, and network refinement. Children prenatally exposed show developmental delays, behavioral and emotional difficulties (Baig et al., \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Bierce et al., \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), with ongoing executive functioning issues including cognitive control, emotional regulation, and behavioral organization problems (Spowart et al., \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Childhood and adolescence involve continued cortical maturation and reward pathway changes. Longitudinal studies report increased emotional and behavioral difficulties over time (Jaekel et al., \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Balalian et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), with cognitive performance, language development, and behavioral regulation differences persisting into adolescence (Yeoh et al., \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Rajaprakash et al., \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2025\u003c/span\u003e).\u003c/p\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003e5.1 Mechanisms of Neurotoxicity\u003c/h2\u003e \u003cp\u003eFentanyl exposure produces neurotoxic effects via molecular, cellular, and neurochemical processes. Opioid exposure is associated with oxidative stress, neuronal apoptosis, and neuroinflammation, affecting neuronal survival and development, particularly in the cortex and hippocampus (Taghizadehghalehjoughi et al., \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Han et al., \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). At the synaptic level, fentanyl-induced \u0026micro;-opioid receptor activation alters intracellular signaling pathways involved in synaptic plasticity and connectivity. Prenatal exposure leads to synaptic dysfunction and neural maturation changes in cortical and limbic circuits that are important for cognition, emotion, and reward processing (Simmons et al., \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Animal studies have demonstrated altered somatosensory processing, suggesting broader neural network organization issues (Alipio et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Transcriptomic studies have indicated that fentanyl exposure alters gene expression patterns linked to reward pathways, sensory processing, and neuronal development, particularly in the nucleus accumbens and sensory cortex (Olusakin et al., \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), suggesting long-term developmental pathway changes. Dopaminergic changes in the mesolimbic system are related to altered reward sensitivity and increased addiction risk (Volkow \u0026amp; Blanco, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Clinical findings reflect these mechanisms: prenatal opioid exposure is linked to emotional dysregulation, behavioral difficulties, and neurodevelopmental conditions associated with limbic and executive system disruptions (Balalian et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Baig et al., \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003e5.2 Cognitive and Behavioral Outcomes\u003c/h2\u003e \u003cp\u003ePrenatal opioid exposure reduces cognitive performance, delays language development, and produces broader developmental deficits (Yeoh et al., \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). Children exposed to cannabis before birth struggle with executive functions, including cognitive control, emotional regulation, and behavioral organization (Spowart et al., \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), displaying externalizing behaviors such as hyperactivity and poor impulse control during early childhood (Baig et al., \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). Prospective infant studies have found developmental delays and early cognitive and behavioral differences within the first year (Bierce et al., \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Longitudinal research indicates that these impairments persist and may intensify (Volkow \u0026amp; Blanco, \u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Growth pattern analyses have shown elevated emotional and behavioral challenges throughout early and middle childhood, particularly in attention, hyperactivity, and emotional regulation (Jaekel et al., \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Population studies have reported higher emotional dysregulation and behavioral disorder rates, likely reflecting changes in the limbic system (Balalian et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Greater opioid exposure during pregnancy, especially prolonged or high-dose exposure, increases the risk of later neurodevelopmental disorders (Wen et al., \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Preclinical evidence supports these outcomes: prenatal opioid exposure disrupts synaptic function, interferes with neural maturation, and alters reward processing, which is linked to behavioral difficulties and increased addiction vulnerability (Dwivedi and Haddad, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2024\u003c/span\u003e; Simmons et al., \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Cortical and limbic networks, particularly those governing executive function and reward, appear to be the most affected (Jiang et al., \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003c/div\u003e"},{"header":"6. Empirical Evidence: Fentanyl Effects on Brain Development","content":"\u003cp\u003eThis section presents detailed analysis of 10 primary empirical studies examining fentanyl's neurodevelopmental effects.\u003c/p\u003e \u003cp\u003eAlipio et al., (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) reported long-term impairments in somatosensory circuit function and behavior following perinatal fentanyl exposure. Using a novel preclinical model, pregnant dams received fentanyl (10 \u0026micro;g/ml) in drinking water from embryonic day 0 through postnatal day 21. Offspring underwent behavioral assessment, in vitro electrophysiology of primary somatosensory cortex (S1) and anterior cingulate cortex, electrocorticography, and morphological analysis of S1 pyramidal neurons. Molecular analysis included cortical mRNA expression of synaptic transmission and neuronal development markers. Exposed mice showed dose-dependent developmental consequences including newborn withdrawal signs and sensory deficits persisting to adolescence. Electrophysiological recordings demonstrated lasting S1 synaptic excitation reduction: decreased release probability, reduced NMDA receptor-mediated postsynaptic currents, decreased miniature excitatory postsynaptic currents frequency, and increased miniature inhibitory postsynaptic currents frequency. Anterior cingulate cortical neurons showed increased synaptic excitation. Electrocorticography recordings revealed suppressed ketamine-evoked γ oscillations. Morphologically, S1 pyramidal neurons showed reduced dendritic complexity, decreased dendritic length, and smaller soma size. Abnormal cortical mRNA expression of receptors involved in synaptic transmission and neuronal growth was observed. This study provided first evidence that perinatal fentanyl exposure produces lasting behavioral, circuit-level, and synaptic effects through adolescence, with region-specific excitation-inhibition balance alterations disrupting somatosensory processing.\u003c/p\u003e \u003cp\u003eYeoh et al., (\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2019\u003c/span\u003e) conducted a comprehensive systematic review and meta-analysis following PRISMA and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. They searched PubMed and Embase through August 2018, identifying 26 peer-reviewed cohort studies comparing 1,455 children with prenatal opioid exposure to 2,982 unexposed controls across ages 6 months to 18 years. Calculated standardized mean differences using random-effects models. Subgroup analyses examined opioid type, socioeconomic controls, and assessment instruments. Prenatal opioid exposure associated with significantly lower cognitive scores at 0\u0026ndash;2 years (d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.52; 95% CI, \u0026minus;\u0026thinsp;0.74 to \u0026minus;\u0026thinsp;0.31; p \u0026lt; .001) and 3\u0026ndash;6 years (d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.38; 95% CI, \u0026minus;\u0026thinsp;0.69 to \u0026minus;\u0026thinsp;0.07; p \u0026lt; .001), corresponding to 5.7\u0026ndash;7.8 IQ point deficits at population level. Motor scores were significantly lower (d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.49; 95% CI, \u0026minus;\u0026thinsp;0.74 to \u0026minus;\u0026thinsp;0.23; p \u0026lt; .001). School-age group (7\u0026ndash;18 years) showed non-significant differences (d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.44; 95% CI, \u0026minus;\u0026thinsp;1.16 to 0.28; p = .23), though limited studies were available. Children with prenatal opioid exposure were three times more likely to have severe intellectual disability compared to general population. This study demonstrated that prenatal opioid exposure shows negative associations with neurocognitive and physical development from as early as 6 months, persisting through school age, with significant public health implications requiring long-term intervention strategies.\u003c/p\u003e \u003cp\u003eTaghizadehghalehjoughi et al., (\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) examined fentanyl and remifentanil effects on neuron damage, oxidative stress, and cholinergic metabolism using CRL-10742 neuron cell cultures. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assays assessed cell viability. Paraoxonase 1 (PON1) activity and total thiol levels measured oxidative stress. Acetylcholinesterase and butyrylcholinesterase activities evaluated cholinergic effects. Tumor Necrosis Factor (TNF), Interleukin-8 (IL-8), and Interleukin-10 (IL-10) gene expression quantified neuroinflammation. Immunohistochemical staining with 4',6-Diamidino-2-Phenylindole (DAPI) and 8-Hydroxy-2'-Deoxyguanosine (8-OHdG) assessed DNA damage. Highest neurotoxic dose was 10 \u0026micro;g/mL for both opioids, reducing neuron cell viability by 61.80% (fentanyl) and 56.89% (remifentanil). Fentanyl upregulated TNF gene expression dose-dependently, indicating neuroinflammation. Both opioids inhibited PON1 activity, suggesting increased oxidative stress. Fentanyl did not increase total thiol levels (unlike remifentanil), indicating inadequate antioxidant response. High concentrations caused DNA damage evidenced by chromatin condensation and 8-OHdG staining. This study showed fentanyl induces neurotoxicity through oxidative stress, neuroinflammation, and DNA damage pathways, with distinct mechanisms from other synthetic opioids, providing mechanistic understanding of developmental neurotoxicity.\u003c/p\u003e \u003cp\u003eSimmons et al., (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) conducted a research work on the Effects of prenatal opioid exposure on synaptic adaptations and behaviors across development. They analyzed synaptic plasticity mechanisms, glutamatergic and GABAergic signaling alterations, and behavioral outcomes across developmental stages. Findings indicated that prenatal opioid exposure leads to altered synaptic plasticity in cortical and limbic regions, with specific disruptions in long-term potentiation and long-term depression mechanisms. The mesolimbic dopamine pathway shows persistent dysregulation, affecting reward processing and increasing addiction vulnerability. Early life stress compounds these effects through glucocorticoid-mediated mechanisms, amplifying synaptic dysfunction in hippocampus and prefrontal cortex. Maternal separation models demonstrate that stress interacts with opioid exposure to produce greater cognitive and emotional dysregulation than either factor alone. This review established that prenatal opioid exposure produces lasting synaptic adaptations that interact with environmental stressors, creating compound vulnerabilities for neuropsychiatric disorders. The convergence of biological and environmental factors necessitates integrated intervention approaches.\u003c/p\u003e \u003cp\u003eOlusakin et al., (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) conducted RNA sequencing across five brain regions (nucleus accumbens [NAc], prelimbic cortex [PrL], ventral tegmental area [VTA], somatosensory cortex [S1], ventrobasal thalamus [VBT]) in perinatal fentanyl-exposed juvenile mice (postnatal day 35) of both sexes. Differential gene expression and weighted gene co-expression network analysis identified exposure-associated transcriptional programs. Findings revealed that VTA exhibited most differentially expressed genes, while robust gene enrichment occurred in NAc. Sex-specific patterns emerged: males showed pronounced mitochondrial respiration gene enrichment in NAc and VTA, plus extracellular matrix and neuronal migration pathway alterations. Females displayed vesicular cycling and synaptic signaling gene changes in NAc, plus mitochondrial respiration, synaptic, and ciliary organization alterations in sensory areas. Rank-rank hypergeometric overlap analysis revealed concordant transcriptional signatures across sexes in PrL, VTA, and S1, but discordance in NAc and VBT. This study concluded that perinatal fentanyl exposure produces distinct, region-specific, and sex-dependent transcriptomic adaptations in reward and sensory circuits. These molecular changes likely underlie structural, functional, and behavioral deficits in exposed offspring, implicating mitochondrial dysfunction and synaptic dysregulation as core mechanisms.\u003c/p\u003e \u003cp\u003eBalalian et al., (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) conducted a systematic review using secondary data from PubMed, Embase, PsycInfo, and Web of Science through May 2022, identifying 79 cohort and case-control studies. Newcastle-Ottawa Scale assessed quality. Studies synthesized by neurodevelopmental domain (cognitive, motor, behavioral) and assessment instrument. Heterogeneity sources systematically examined. Findings indicated significant heterogeneity existed across studies due to varying exposure ascertainment methods, pregnancy timing assessments, opioid types (non-medical, medication-assisted treatment, prescribed), co-exposures, and comparison group selection. Despite heterogeneity precluding meta-analysis, consistent negative trends emerged: cognitive skills, motor development, and behavioral regulation were generally adversely affected by prenatal opioid exposure. Medication-assisted treatment (methadone/buprenorphine) showed better outcomes than non-medical opioid use but still produced deficits compared to unexposed controls. This study concluded that while methodological diversity complicates quantitative synthesis, the weight of evidence demonstrates consistent negative associations between prenatal opioid exposure and multiple neurodevelopmental domains. Standardized assessment protocols are urgently needed to clarify dose-response relationships and optimal intervention timing.\u003c/p\u003e \u003cp\u003eSpowart et al., (\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) conducted a prospective cohort study with third follow-up assessment of 153 children born to methadone-maintained opioid-dependent mothers (2008\u0026ndash;2010). At ages 8\u0026ndash;10 years, 33 traceable children (exposed group) and matched controls were assessed using Strengths and Difficulties Questionnaire (SDQ) and Behavior Rating Inventory of Executive Function, Second Edition (BRIEF-2). Regression modeling controlled for confounding factors including maternal tobacco use. Findings indicated that no group differences emerged on SDQ subscales for emotional symptoms, conduct problems, or peer relationships. However, marginally higher proportion of exposed children scored in high/very high range for hyperactivity. Critically, exposed children scored significantly higher on all BRIEF-2 indices: behavioral regulation (p \u0026lt; .05), emotional regulation (p \u0026lt; .05), cognitive regulation (p \u0026lt; .01), and global executive composite (p \u0026lt; .01). After controlling for maternal tobacco use, effect sizes reduced but remained clinically significant. This study concluded that prenatal methadone exposure is associated with specific executive function deficits in middle childhood, distinct from general behavioral problems. These findings support targeted neurodevelopmental monitoring and intervention for opioid-exposed children, with particular attention to prefrontal cortex-mediated functions.\u003c/p\u003e \u003cp\u003eBaig et al., (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) conducted a retrospective cohort study analyzing 94 children with documented prenatal opioid exposure evaluated with Child Behavior Checklist (CBCL) at age 2 years. Multivariable logistic regression identified factors associated with borderline/clinical range scores, including Bayley-III motor scores, discharge disposition, and neonatal opioid withdrawal syndrome treatment modalities. Findings reported that thirty children (30%) scored in borderline/clinical range on CBCL total problems, with 27% scoring borderline/clinical for externalizing problems specifically. Lower Bayley-III motor scores and discharge home with mother under safety plan were associated with borderline/clinical externalizing problems. Conversely, medication treatment for neonatal opioid withdrawal syndrome (particularly with clonidine or phenobarbital) was associated with normal-range scores across all CBCL broadband measures. This study concluded that specific clinical factors including motor development status and postnatal care arrangements predict behavioral and emotional challenges in opioid-exposed toddlers. Importantly, appropriate pharmacological management of withdrawal syndrome may have protective effects against later behavioral problems, suggesting critical intervention windows.\u003c/p\u003e \u003cp\u003eWen et al., (\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) conducted a retrospective cohort analysis examining prescription opioid exposure during pregnancy and subsequent neurodevelopmental disorder diagnoses in early childhood. Cumulative opioid dose and duration of exposure were quantified from prescription records. Children followed for neurodevelopmental disorder diagnoses (autism spectrum disorder, ADHD, developmental delay) using diagnostic codes. Results indicated that higher cumulative prenatal opioid doses and longer exposure durations were associated with increased neurodevelopmental disorder risk. The association was dose-dependent: higher exposures showed significant relationships with neurodevelopmental disorder risk, while lower exposures did not reach statistical significance. This pattern suggests a threshold effect or dose-response relationship between prenatal opioid exposure and adverse neurodevelopmental outcomes. This study concluded that the dose-dependent relationship between prenatal opioid exposure and neurodevelopmental disorder risk supports causal inference and informs clinical guidelines for opioid prescribing during pregnancy. Minimizing dose and duration may reduce developmental risks.\u003c/p\u003e \u003cp\u003eRajaprakash et al., (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2025\u003c/span\u003e) conducted a systematic review synthesizing evidence on prenatal opioid exposure and neonatal opioid withdrawal syndrome outcomes from birth through early adulthood. Studies assessed for structural brain changes (magnetic resonance imaging/diffusion tensor imaging), cognitive outcomes, behavioral trajectories, and functional impairments across developmental stages. Findings show that prenatal opioid exposure leading to neonatal opioid withdrawal syndrome was associated with cognitive delays, language deficits, motor impairments, and higher risk for ADHD and behavioral disorders through adolescence. Structural brain alterations included white matter disruptions and altered connectivity patterns visible on neuroimaging. These effects persisted even after controlling for environmental confounders, suggesting direct biological mechanisms. Adolescents with prenatal exposure history showed increased substance use vulnerability and educational underachievement. This review concluded that prenatal opioid exposure produces a neurodevelopmental syndrome with lasting structural and functional brain changes extending into early adulthood. The persistence of deficits across decades necessitates longitudinal support systems and early intervention programs.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSummary of Empirical Studies on Fentanyl/Opioid Neurodevelopmental Effects\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAuthors (Year)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eStudy Type\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSample/Model\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eKey Brain Regions\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePrimary Findings\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAlipio et al., (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnimal (Mouse)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePerinatal fentanyl exposure\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSomatosensory cortex (S1), anterior cingulate\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eReduced synaptic excitation, dendritic complexity loss, altered E/I balance\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eYeoh et al., (\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2019\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMeta-analysis (Human)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26 studies, 1,455 exposed children\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGlobal neurodevelopment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCognitive deficit d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.52 (infancy), d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.38 (preschool); motor deficit d\u0026thinsp;=\u0026thinsp;\u0026minus;\u0026thinsp;0.49\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eTaghizadehghalehjoughi et al., (\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eExperimental (In Vitro)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNeuron cell culture (CRL-10742)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCortical/hippocampal neurons\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e61.8% cell death at 10\u0026micro;g/mL; oxidative stress, DNA damage, neuroinflammation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSimmons et al., (\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e2023\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eReview (Preclinical/Clinical)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSynthesis of POE\u0026thinsp;+\u0026thinsp;ELS studies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eHippocampus, limbic system, PFC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSynaptic plasticity disruption; reward circuit dysregulation; stress interaction\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOlusakin et al., (\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAnimal (Mouse)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTranscriptomic profiling\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNAc, VTA, PrL, S1, VBT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSex-specific gene expression changes; mitochondrial dysfunction; synaptic alterations\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBalalian et al., (\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSystematic Review (Human)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e79 studies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGlobal neurodevelopment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eConsistent negative trends across cognitive, motor, behavioral domains\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSpowart et al., (\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eClinical Cohort\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33 children (ages 8\u0026ndash;10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eExecutive function networks (PFC)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSignificant BRIEF-2 deficits in behavioral, emotional, cognitive regulation\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBaig et al., (\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRetrospective Cohort\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e94 children (age 2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBehavioral/emotional systems\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e30% borderline/clinical CBCL scores; NOWS treatment protective\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eWen et al., (\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e2021\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRetrospective Cohort\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePrescription opioid exposure\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGlobal neurodevelopment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eDose-dependent NDD risk; higher doses associated with increased risk\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRajaprakash et al., (\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e2025\u003c/span\u003e)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSystematic Review (Human/Animal)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBirth to early adulthood\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eWhite matter, cortical, limbic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003ePersistent structural brain changes; cognitive/behavioral deficits; ADHD risk\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cem\u003eSource: Author's Compilation (2026).\u003c/em\u003e \u003c/p\u003e"},{"header":"7. Research Gap and Contribution to Existing Literature","content":"\u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003e7.1 Identified Gap\u003c/h2\u003e \u003cp\u003eDespite extensive literature on fentanyl as an opioid analgesic, its abuse potential, and public health implications, a critical gap remains regarding the integration of fentanyl's specific chemical properties with neurodevelopmental mechanisms. Recent comprehensive reviews have examined various aspects of the opioid crisis, yet none have systematically connected fentanyl's molecular structure to its developmental neurotoxicity. For instance, Volkow and Blanco, (\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) examined the changing opioid crisis and neurobiological vulnerabilities but focused primarily on addiction mechanisms rather than developmental toxicology; Mattson et al., (\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) analyzed geographic and temporal trends in synthetic opioid overdose deaths without addressing chemical structure-brain development relationships; Ciccarone, (\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) characterized the \"fourth wave\" of the opioid crisis involving polysubstance use but did not examine molecular mechanisms of neurodevelopmental harm; O'Donnell et al., (\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e2021\u003c/span\u003e) documented overdose death characteristics from illicitly manufactured fentanyls without exploring developmental exposure consequences; Hauser and Knapp, (\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e2018\u003c/span\u003e) reviewed how opiate drugs disrupt neuronal and glial maturation but focused broadly on opioid class effects rather than fentanyl-specific chemistry; and Dwivedi and Haddad, (\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) investigated maternal opioid use disorder using brain organoid technology but emphasized clinical populations over chemical mechanisms. This review addresses the specific gap by systematically examining how fentanyl's phenylpiperidine structure, lipophilicity (logP\u0026thinsp;~\u0026thinsp;4.0), and high \u0026micro;-opioid receptor affinity translate into synaptic disruption, oxidative stress, and lasting cognitive-behavioral deficits when exposure occurs during critical neurodevelopmental periods.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003e7.2 Contribution to Existing Literature\u003c/h2\u003e \u003cp\u003eThis review makes three distinct contributions: firstly, chemical-neurodevelopmental integration connecting fentanyl's verified physicochemical properties (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e) with empirical neurodevelopmental outcomes, demonstrating how molecular structure determines blood-brain barrier penetration and receptor-mediated developmental toxicity. Secondly, empirical synthesis comprehensive analysis of 10 primary empirical studies (2019\u0026ndash;2025) specifically examining fentanyl/opioid effects on brain development, providing mechanistic insights from transcriptomics (Olusakin et al., \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), electrophysiology (Alipio et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e), and clinical neuropsychology (Spowart et al., \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). Lastly, translational framework evidence-based foundation for chemistry-informed interventions, connecting computational molecular dynamics research with public health prevention strategies aligned with Sustainable Development Goal 3.5.\u003c/p\u003e \u003c/div\u003e"},{"header":"8. Future Research Directions","content":"\u003cp\u003eFuture research must prioritize computational chemistry and structure-based drug design to address fentanyl's neurodevelopmental toxicity. Recent molecular dynamics studies have elucidated critical binding mechanisms that inform safer analog development.\u003c/p\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003e8.1 Computational Chemistry Approaches\u003c/h2\u003e \u003cp\u003e \u003cstrong\u003eMolecular Dynamics Insights\u003c/strong\u003e \u003cp\u003eResearch utilizing X-ray crystallography of the \u0026micro;-opioid receptor in complex with fentanyl has identified detailed interaction profiles, providing structural bases for binding affinity and abuse potential (Vo et al., \u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e2021\u003c/span\u003e). Studies have employed weighted ensemble molecular dynamics and metadynamics simulations to characterize fentanyl's dual binding modes at \u0026micro;-opioid receptor involving both the canonical Asp3.32 salt bridge and a secondary His6.52 hydrogen bonding configuration (Xie et al., \u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eKey Finding\u003c/strong\u003e \u003cp\u003eFentanyl's unique ability to adopt a \"deep binding\" mode through hydrogen bonding with His297 (when protonated at Nδ) creates prolonged receptor residence times nearly 1\u0026ndash;2 orders of magnitude longer than alternative protonation states. This molecular mechanism explains fentanyl's exceptional potency and suggests that modifying the piperidine nitrogen interaction profile could reduce both analgesic efficacy and developmental toxicity.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003e8.2 Structure-Based Design of Safer Analogs\u003c/h2\u003e \u003cp\u003eResearch demonstrates that fentanyl analogs with modified N-chain volumes and anilide aromatic ring substitutions show nonlinear structure-activity relationships (Vardanyan \u0026amp; Hruby, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Lipiński et al., \u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). Optimal binding affinity occurs with medium-sized substituents, while both smaller and larger modifications reduce potency.\u003c/p\u003e \u003cp\u003e \u003cb\u003eFuture Direction\u003c/b\u003e: Computational screening of fentanyl derivatives with: (1) Modified piperidine substitutions reducing His6.52 binding mode stability; (2) Altered lipophilicity (reducing logP below 4.0) to slow blood-brain barrier penetration during developmental exposure; (3) Enhanced plasma protein binding to reduce free drug concentration available for central nervous system entry.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003e8.3 Neuroprotective Chemistry Strategies\u003c/h2\u003e \u003cp\u003eBuilding upon Taghizadehghalehjoughi et al.'s (\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) findings regarding oxidative stress pathways, future research should investigate: Antioxidant co-formulations combining fentanyl with thiol-replenishing agents (as remifentanil naturally increases total thiol levels); Pro-drug approaches developing esterase-activated fentanyl pro-drugs requiring metabolic conversion, thereby reducing acute central nervous system exposure peaks during accidental ingestion; and Receptor-selective analogs exploiting computational models to design \u0026micro;-opioid receptor agonists with reduced β-arrestin recruitment (biased agonism), potentially preserving analgesia while minimizing receptor internalization and developmental signaling disruption.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec25\" class=\"Section2\"\u003e \u003ch2\u003e8.4 Public Awareness and Chemistry Education\u003c/h2\u003e \u003cp\u003eThe devastating neurodevelopmental effects documented in this review particularly the 30% rate of clinical-range behavioral problems in exposed toddlers (Baig et al., \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e) and persistent executive deficits through age 10 (Spowart et al., \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) demand enhanced public awareness campaigns. Chemistry education should emphasize: structural features enabling rapid central nervous system penetration (lipophilicity, small molecular weight); dose-response relationships showing no \"safe\" exposure level during pregnancy; and mechanisms of placental transfer and fetal brain vulnerability.\u003c/p\u003e \u003c/div\u003e"},{"header":"9. Conclusion","content":"\u003cp\u003eThis systematic review examined the chemistry of fentanyl and its implications for brain development through integration of molecular pharmacology and empirical neurodevelopmental research. Key findings demonstrate that fentanyl's phenylpiperidine structure (C₂₂H₂₈N₂O), exceptional lipophilicity (logP\u0026thinsp;~\u0026thinsp;4.0), and high \u0026micro;-opioid receptor affinity create unique risks for developmental neurotoxicity when exposure occurs during critical periods. Methodologically, this review synthesized 10 PRISMA-selected studies (2018\u0026ndash;2025) employing diverse approaches: preclinical electrophysiology and transcriptomics (Alipio et al., \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Olusakin et al., \u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), clinical neuropsychological assessment (Spowart et al., \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Baig et al., \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2024\u003c/span\u003e), systematic meta-analyses (Yeoh et al., \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Balalian et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2023\u003c/span\u003e), and in vitro neurotoxicity assays (Taghizadehghalehjoughi et al., \u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e2024\u003c/span\u003e). This methodological diversity strengthens confidence in convergent findings while highlighting heterogeneity requiring standardized future research. The findings of this research establish that perinatal fentanyl exposure produces: (1) lasting somatosensory circuit dysfunction through altered excitation-inhibition balance; (2) sex-specific transcriptomic alterations in reward regions involving mitochondrial dysfunction and synaptic dysregulation; (3) dose-dependent cognitive and motor deficits equivalent to 5.7\u0026ndash;7.8 IQ point reductions; (4) executive function impairments persisting to middle childhood; and (5) structural brain changes visible through adolescence. Mechanistically, these effects derive from fentanyl's rapid blood-brain barrier penetration, oxidative stress induction, DNA damage, and disruption of neurotransmitter homeostasis during synaptogenesis and myelination.\u003c/p\u003e \u003cp\u003eThis review advances Sustainable Development Goal 3 (Target 3.5) by providing an evidence base for reducing substance-related harm through chemistry-informed prevention, and contributes to Sustainable Development Goal 4.7 by integrating health risk knowledge into scientific education. The chemistry-brain development framework established here offers a template for investigating neurodevelopmental risks of emerging synthetic opioids and designing molecular interventions to protect vulnerable developing brains.\u003c/p\u003e \u003cp\u003e \u003cb\u003eRecommendations\u003c/b\u003e \u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eClinical\u003c/b\u003e: Implement mandatory neurodevelopmental screening for all opioid-exposed children from infancy through adolescence.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eRegulatory\u003c/b\u003e: Restrict fentanyl prescribing during pregnancy to cases where alternatives are contraindicated, with mandatory neonatal follow-up protocols.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eResearch\u003c/b\u003e: Prioritize computational chemistry studies elucidating structure-neurotoxicity relationships to guide safer analog design.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003ePublic Health\u003c/b\u003e: Deploy chemistry-informed awareness campaigns emphasizing fentanyl's unique developmental risks compared to other opioids.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003e \u003cb\u003eHarm Reduction\u003c/b\u003e: Expand access to medication-assisted treatment (methadone/buprenorphine) which shows better neurodevelopmental outcomes than non-medical opioid use, while ensuring long-term developmental monitoring.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAlipio JB, Haga C, Fox ME, Arakawa K, Balaji R, Cramer N, Lobo MK, Keller A (2021) Perinatal fentanyl exposure leads to long-lasting impairments in somatosensory circuit function and behavior. J Neurosci 41(15):3400\u0026ndash;3417. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1523/JNEUROSCI.2470-20.2020\u003c/span\u003e\u003cspan address=\"10.1523/JNEUROSCI.2470-20.2020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAlzu'bi A, Baker B, Al-Trad W, Zoubi BA, AbuAlArjah MS, Abu-El-Rub MI, Tahat E, Helaly L, Ghorab AMNZ, El-Huneidi DS, W. and, Al-Zoubi RM (2024) The impact of chronic fentanyl administration on the cerebral cortex in mice: Molecular and histological effects. Brain Res Bull 209:110917. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.brainresbull.2024.110917\u003c/span\u003e\u003cspan address=\"10.1016/j.brainresbull.2024.110917\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArmenian P, Vo KT, Barr-Walker J, Lynch KL (2018) 'Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review', \u003cem\u003eNeuropharmacology\u003c/em\u003e, 134(Pt A), pp. 121\u0026ndash;132. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.neuropharm.2017.10.016\u003c/span\u003e\u003cspan address=\"10.1016/j.neuropharm.2017.10.016\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaig N, Sun Q, Liu C, Ehrlich S, Merhar S, McAllister J (2024) Neurobehavioral problems at age 2 years in children with prenatal opioid exposure. J Perinatol 44(8):1146\u0026ndash;1151. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41372-024-01913-7\u003c/span\u003e\u003cspan address=\"10.1038/s41372-024-01913-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBalalian AA, Graeve R, Richter M, Fink A, Kielstein H, Martins SS, Philbin MM, Factor-Litvak P (2023) Prenatal exposure to opioids and neurodevelopment in infancy and childhood: A systematic review. Front Pead 11:1071889. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fped.2023.1071889\u003c/span\u003e\u003cspan address=\"10.3389/fped.2023.1071889\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarletta C, Di Natale V, Esposito M, Chisari M, Cocimano G, Di Mauro L, Salerno M, Sessa F (2025) The rise of fentanyl: Molecular aspects and forensic investigations. Int J Mol Sci 26(2):444. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/ijms26020444\u003c/span\u003e\u003cspan address=\"10.3390/ijms26020444\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBierce L, Tabachnick AR, Eiden RD, Dozier M, Labella M (2023) A 12-month follow-up of infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use. Neurotoxicol Teratol 97:107176. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.ntt.2023.107176\u003c/span\u003e\u003cspan address=\"10.1016/j.ntt.2023.107176\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCastro EM, Lotfipour S, Leslie FM (2023) Nicotine on the developing brain. Pharmacol Res 190:106716. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.phrs.2023.106716\u003c/span\u003e\u003cspan address=\"10.1016/j.phrs.2023.106716\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCenters for Disease Control and Prevention (CDC) (2025) \u003cem\u003eUnderstanding the opioid overdose epidemic\u003c/em\u003e. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html\u003c/span\u003e\u003cspan address=\"https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCiccarone D (2021) The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry 34(4):344\u0026ndash;350. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/YCO.0000000000000717\u003c/span\u003e\u003cspan address=\"10.1097/YCO.0000000000000717\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eClinton HA, Thangada S, Gill JR, Mirizzi A, Logan SB (2021) Improvements in toxicology testing to identify fentanyl analogs and other novel synthetic opioids in fatal drug overdoses, Connecticut, January 2016\u0026ndash;June 2019. Public Health Rep 136(1 suppl):80S\u0026ndash;86S. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1177/00333549211042829\u003c/span\u003e\u003cspan address=\"10.1177/00333549211042829\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDavis MP, Behm B (2020) Reasons to avoid fentanyl. Annals Palliat Med 9(2):410\u0026ndash;418. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.21037/apm.2020.01.12\u003c/span\u003e\u003cspan address=\"10.21037/apm.2020.01.12\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDong T, Lei S, Ding G (2025) Comparative effectiveness of propofol-sufentanil vs propofol-fentanyl in elderly patients undergoing transurethral resection of the prostate. Ther Clin Risk Manag 21:1773\u0026ndash;1782. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.2147/TCRM.S549323\u003c/span\u003e\u003cspan address=\"10.2147/TCRM.S549323\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDwivedi I, Haddad GG (2024) Investigating the neurobiology of maternal opioid use disorder and prenatal opioid exposure using brain organoid technology. Front Cell Neurosci 18:1403326. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fncel.2024.1403326\u003c/span\u003e\u003cspan address=\"10.3389/fncel.2024.1403326\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2025) \u003cem\u003eFentanyl drug profile\u003c/em\u003e. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.euda.europa.eu/publications/drug-profiles/fentanyl_en\u003c/span\u003e\u003cspan address=\"https://www.euda.europa.eu/publications/drug-profiles/fentanyl_en\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFinancial Action Task Force (FATF) (2022) \u003cem\u003eMoney laundering from fentanyl and synthetic opioids\u003c/em\u003e. Paris: FATF. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.fatf-gafi.org/publications/methodsandtrends/documents/money-laundering-fentanyl-syntheticopioids.html\u003c/span\u003e\u003cspan address=\"https://www.fatf-gafi.org/publications/methodsandtrends/documents/money-laundering-fentanyl-syntheticopioids.html\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFriedman JR, Romero R, Funnell A, Goodman-Meza D, Shover CL (2025) What does polysubstance really mean? Comparing drug-involved deaths in CDC records vs. detailed medical examiner data from Los Angeles. Int J Drug Policy 148:105129. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.drugpo.2025.105129\u003c/span\u003e\u003cspan address=\"10.1016/j.drugpo.2025.105129\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHan Y, Cao L, Yuan K et al (2022) Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse. Neurosci Bull 38:1365\u0026ndash;1382. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s12264-022-00872-3\u003c/span\u003e\u003cspan address=\"10.1007/s12264-022-00872-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHauser KF, Knapp PE (2018) Opiate drugs with abuse liability hijack the endogenous opioid system to disrupt neuronal and glial maturation in the central nervous system. Front Pead 5:294. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fped.2017.00294\u003c/span\u003e\u003cspan address=\"10.3389/fped.2017.00294\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHenthorn TK, Mikulich-Gilbertson SK (2018) \u0026micro;-Opioid receptor agonists: Do they have utility in the treatment of acute pain? Anesthesiology 128(5):867\u0026ndash;870. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1097/ALN.0000000000002126\u003c/span\u003e\u003cspan address=\"10.1097/ALN.0000000000002126\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHussien RM, Rabie AH (2019) Sequential intrathecal injection of fentanyl and hyperbaric bupivacaine at different rates: Does it make a difference? A randomized controlled trial. Korean J Anesthesiology 72(2):150\u0026ndash;155. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.4097/kja.d.18.00173\u003c/span\u003e\u003cspan address=\"10.4097/kja.d.18.00173\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJaekel J, Kim HM, Lee SJ, Schwartz A, Henderson JMT, Woodward LJ (2021) Emotional and behavioral trajectories of 2 to 9 years old children born to opioid-dependent mothers. Res Child Adolesc Psychopathol 49(4):443\u0026ndash;457. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s10802-020-00766-w\u003c/span\u003e\u003cspan address=\"10.1007/s10802-020-00766-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJalali MS, Botticelli M, Hwang RC (2020) The opioid crisis: A contextual, social-ecological framework. Health Res Policy Syst 18:87. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1186/s12961-020-00596-8\u003c/span\u003e\u003cspan address=\"10.1186/s12961-020-00596-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJel\u0026iacute;nkov\u0026aacute; R (2024) Fentanyl and its derivatives: Pharmacology, use and abuse, and detection possibilities. Contemporary Topics in Patient Safety, vol 3. IntechOpen, London. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.5772/intechopen.113090\u003c/span\u003e\u003cspan address=\"10.5772/intechopen.113090\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJiang W, Merhar SL, Zeng Z, Zhu Z, Yin W, Zhou Z, Wang L, He L, Vannest J, Lin W (2022) Neural alterations in opioid-exposed infants revealed by edge-centric brain functional networks. Brain Commun 4(3):fcac112. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1093/braincomms/fcac112\u003c/span\u003e\u003cspan address=\"10.1093/braincomms/fcac112\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKaratayev O, Collier AD, Targoff SR, Leibowitz SF (2024) Neurological disorders induced by drug use: Effects of adolescent and embryonic drug exposure on behavioral neurodevelopment. Int J Mol Sci 25(15):8341. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/ijms25158341\u003c/span\u003e\u003cspan address=\"10.3390/ijms25158341\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLarnder A, Saatchi A, Borden SA, Moa B, Gill CG, Wallace B, Hore D (2022) Variability in the unregulated opioid market in the context of extreme rates of overdose. Drug Alcohol Depend 235:109427. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.drugalcdep.2022.109427\u003c/span\u003e\u003cspan address=\"10.1016/j.drugalcdep.2022.109427\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeppert W, Malec-Milewska M, Zajaczkowska R, Wordliczek J (2018) Transdermal and topical drug administration in the treatment of pain. Molecules 23(3):681. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/molecules23030681\u003c/span\u003e\u003cspan address=\"10.3390/molecules23030681\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLipiński PFJ, Jarończyk M, Dobrowolski JC, Sadlej J (2019) Molecular dynamics of fentanyl bound to \u0026micro;-opioid receptor. J Mol Model 25(5):144. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s00894-019-3999-2\u003c/span\u003e\u003cspan address=\"10.1007/s00894-019-3999-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eManuel JI, Baslock D, DeBarros T, Halliday T, Pietruszewski P, Plante A, Woods Razaa J, Sloyer W, Stanhope V (2023) Factors associated with indirect exposure to and knowledge of fentanyl among youth. J Adolesc Health 74(2):191\u0026ndash;198. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jadohealth.2023.08.040\u003c/span\u003e\u003cspan address=\"10.1016/j.jadohealth.2023.08.040\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL (2021) 'Trends and geographic patterns in drug and synthetic opioid overdose deaths \u0026mdash; United States, 2013\u0026ndash;2019', \u003cem\u003eMMWR Morbidity and Mortality Weekly Report\u003c/em\u003e, 70, pp. 202\u0026ndash;207. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.15585/mmwr.mm7006a4\u003c/span\u003e\u003cspan address=\"10.15585/mmwr.mm7006a4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNational Center for Biotechnology Information (2026) \u003cem\u003ePubChem compound summary for CID 3345, fentanyl\u003c/em\u003e. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/Fentanyl\u003c/span\u003e\u003cspan address=\"https://pubchem.ncbi.nlm.nih.gov/compound/Fentanyl\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eO'Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J (2021) 'Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls \u0026mdash; United States, 2019\u0026ndash;2020', \u003cem\u003eMMWR Morbidity and Mortality Weekly Report\u003c/em\u003e, 70, pp. 1740\u0026ndash;1746. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.15585/mmwr.mm7050e3\u003c/span\u003e\u003cspan address=\"10.15585/mmwr.mm7050e3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOlusakin J, Kumar G, Basu M, Calarco CA, Fox ME, Alipio JB, Haga C, Turner MD, Keller A, Ament SA, Lobo MK (2023) Transcriptomic profiling of reward and sensory brain areas in perinatal fentanyl exposed juvenile mice. Neuropsychopharmacology 48(12):1724\u0026ndash;1734. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41386-023-01639-8\u003c/span\u003e\u003cspan address=\"10.1038/s41386-023-01639-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePage MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u0026oacute;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D (2021) 'The PRISMA 2020 statement: An updated guideline for reporting systematic reviews', \u003cem\u003eBMJ\u003c/em\u003e, 372, p. n71. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1136/bmj.n71\u003c/span\u003e\u003cspan address=\"10.1136/bmj.n71\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePickens CM, Park J, Casillas SM, Smith K, Hoots BE, Vivolo-Kantor AM, O'Donnell J (2025) Trends in suspected fentanyl-involved nonfatal overdose emergency department visits, by age group, sex, and race and ethnicity \u0026mdash; United States, October 2020\u0026ndash;March 2024. MMWR Morbidity Mortal Wkly Rep 74(16):282\u0026ndash;287. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.15585/mmwr.mm7416a2\u003c/span\u003e\u003cspan address=\"10.15585/mmwr.mm7416a2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePosa F, Porfilio A (2025) A review on fentanyl and the neuroscientific roots of criminal behaviour: Forensic and legal reflections. Med Res Archives 13(11). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.18103/mra.v13i11.0000\u003c/span\u003e\u003cspan address=\"10.18103/mra.v13i11.0000\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRajaprakash M, West S, Jayakumar S, Robinson J, Burton VJ, Gerner G (2025) 'Neurodevelopmental outcomes of prenatal opioid exposure and neonatal opioid withdrawal syndrome: A systematic review from birth to early adulthood', \u003cem\u003eJournal of Perinatology\u003c/em\u003e. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41372-025-02496-7\u003c/span\u003e\u003cspan address=\"10.1038/s41372-025-02496-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRamos-Matos CF, Bistas KG, Lopez-Ojeda W (2023) 'Fentanyl', in \u003cem\u003eStatPearls\u003c/em\u003e. Treasure Island, FL: StatPearls Publishing. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ncbi.nlm.nih.gov/books/NBK459275/\u003c/span\u003e\u003cspan address=\"https://www.ncbi.nlm.nih.gov/books/NBK459275/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eScholl L, Seth P, Kariisa M, Wilson N, Baldwin G (2018) Drug and opioid-involved overdose deaths \u0026mdash; United States, 2013\u0026ndash;2017. MMWR Morbidity Mortal Wkly Rep 67(51\u0026ndash;52):1419\u0026ndash;1427. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.15585/mmwr.mm675152e1\u003c/span\u003e\u003cspan address=\"10.15585/mmwr.mm675152e1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimmons SC, Grecco GG, Atwood BK, Nugent FS (2023) 'Effects of prenatal opioid exposure on synaptic adaptations and behaviors across development', \u003cem\u003eNeuropharmacology\u003c/em\u003e, 222, p. 109312. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.neuropharm.2022.109312\u003c/span\u003e\u003cspan address=\"10.1016/j.neuropharm.2022.109312\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSpowart KM, Reilly K, Mactier H, Hamilton R (2023) Executive functioning, behavioural, emotional, and cognitive difficulties in school-aged children prenatally exposed to methadone. Front Pead 11:1118634. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fped.2023.1118634\u003c/span\u003e\u003cspan address=\"10.3389/fped.2023.1118634\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStanley TH (2014) The fentanyl story. J Pain 15(12):1215\u0026ndash;1226. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.jpain.2014.08.010\u003c/span\u003e\u003cspan address=\"10.1016/j.jpain.2014.08.010\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSteinfeld MR, Torregrossa MM (2023) Consequences of adolescent drug use. Translational Psychiatry 13:313. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41398-023-02590-4\u003c/span\u003e\u003cspan address=\"10.1038/s41398-023-02590-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTaghizadehghalehjoughi A, Naldan ME, Yeni Y, Genc S, Hacimuftuoglu A, Isik M, Necip A, Bolat İ, Yildirim S, Beydemir S, Baykan M (2024) Effect of fentanyl and remifentanil on neuron damage and oxidative stress during induction neurotoxicity. J Cell Mol Med 28(4):e18118. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/jcmm.18118\u003c/span\u003e\u003cspan address=\"10.1111/jcmm.18118\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVardanyan RS, Hruby VJ (2014) Fentanyl-related compounds and derivatives: Current status and future prospects for pharmaceutical applications. Future Med Chem 6(4):385\u0026ndash;412. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.4155/fmc.13.215\u003c/span\u003e\u003cspan address=\"10.4155/fmc.13.215\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVo QN, Mahinthichaichan P, Shen J, Ellis CR, Zhang S, Gross ML, Liu J (2021) How \u0026micro;-opioid receptor recognizes fentanyl. Nat Commun 12:984. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41467-021-21262-9\u003c/span\u003e\u003cspan address=\"10.1038/s41467-021-21262-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVolkow ND, Blanco C (2021) The changing opioid crisis: Development, challenges and opportunities. Mol Psychiatry 26(1):218\u0026ndash;233. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1038/s41380-020-0661-4\u003c/span\u003e\u003cspan address=\"10.1038/s41380-020-0661-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWen X, Lawal OD, Belviso N, Matson KL, Wang S, Quilliam BJ, Meador KJ (2021) Association between prenatal opioid exposure and neurodevelopmental outcomes in early childhood: A retrospective cohort study. Drug Saf 44(8):863\u0026ndash;875. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1007/s40264-021-01080-0\u003c/span\u003e\u003cspan address=\"10.1007/s40264-021-01080-0\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilde M, Pichini S, Pacifici R, Tagliabracci A, Busard\u0026ograve; FP, Auw\u0026auml;rter V, Solimini R (2019) Metabolic pathways and potencies of new fentanyl analogs. Front Pharmacol 10:238. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3389/fphar.2019.00238\u003c/span\u003e\u003cspan address=\"10.3389/fphar.2019.00238\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilliamson J, Kermanizadeh A (2024) A review of toxicological profile of fentanyl \u0026mdash; a 2024 update. Toxics 12(10):690. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.3390/toxics12100690\u003c/span\u003e\u003cspan address=\"10.3390/toxics12100690\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWorld Health Organization (WHO) (2025) \u003cem\u003eOpioid overdose: Fact sheet\u003c/em\u003e. Available at: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.who.int/news-room/fact-sheets/detail/opioid-overdose\u003c/span\u003e\u003cspan address=\"https://www.who.int/news-room/fact-sheets/detail/opioid-overdose\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXie B, Goldberg A, Shi L (2022) A comprehensive evaluation of the potential binding poses of fentanyl and its analogs at the \u0026micro;-opioid receptor. Comput Struct Biotechnol J 20:2309\u0026ndash;2321. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1016/j.csbj.2022.05.013\u003c/span\u003e\u003cspan address=\"10.1016/j.csbj.2022.05.013\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYeoh SL, Eastwood J, Wright IM, Morton R, Melhuish E, Ward M, Oei JL (2019) Cognitive and motor outcomes of children with prenatal opioid exposure: A systematic review and meta-analysis. JAMA Netw Open 2(7):e197025. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1001/jamanetworkopen.2019.7025\u003c/span\u003e\u003cspan address=\"10.1001/jamanetworkopen.2019.7025\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":true,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Fentanyl, Neurodevelopment, µ-Opioid Receptors, Brain Toxicity, Chemistry, Prenatal Exposure, Adolescent Brain","lastPublishedDoi":"10.21203/rs.3.rs-9288777/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-9288777/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eSince its discovery in 1960 by Paul Janssen, fentanyl has emerged as one of the central substances in the global opioid crisis because of its high potency (50\u0026ndash;100 times that of morphine) and rapid penetration through the blood-brain barrier. Following the PRISMA 2020 guidelines for reporting systematic reviews and meta-analyses, this systematic review synthesizes the results of ten empirical studies (2018\u0026ndash;2025) analyzing fentanyl's chemical characteristics and neurodevelopmental effects. The findings demonstrate that fentanyl disrupts synaptic development through \u0026micro;-opioid receptor (MOR) agonism, induces neuronal apoptosis via oxidative stress pathways, alters gene expression in reward circuits, and produces lasting cognitive deficits. After perinatal exposure, preclinical studies have revealed persistent dysfunction of the somatosensory system and transcriptomic alterations in the nucleus accumbens. Clinical meta-analyses have demonstrated that children exposed to such chemicals suffer from serious cognitive and motor impairments. This review addresses the critical gap in integrating the specific molecular chemistry of fentanyl, its phenylpiperidine structure (C₂₂H₂₈N₂O), lipophilicity (logP\u0026thinsp;~\u0026thinsp;4.0), and high receptor affinity with neurodevelopmental mechanisms. Future research should focus on computational chemistry approaches to design safer analogs and neuroprotective strategies. This study contributes to Sustainable Development Goal 3 (Target 3.5) by providing an evidence base for chemistry-informed harm reduction and prevention strategies.\u003c/p\u003e","manuscriptTitle":"The Chemistry of Fentanyl and Its Implications on Brain Development: A Review","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-04-03 06:29:43","doi":"10.21203/rs.3.rs-9288777/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5e5b90b9-20f3-4a92-a509-474251769500","owner":[],"postedDate":"April 3rd, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":65621784,"name":"Biological Chemistry"},{"id":65621785,"name":"Special Education"},{"id":65621786,"name":"Chemical Biology"}],"tags":[],"updatedAt":"2026-04-03T06:29:43+00:00","versionOfRecord":[],"versionCreatedAt":"2026-04-03 06:29:43","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-9288777","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-9288777","identity":"rs-9288777","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}